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ABSTRACT
The mammalian Nell1 gene encodes a PKC-β1 binding protein that belongs to a
new class of cell-signaling molecules controlling cell growth and differentiation.
Overexpression of NELL1/Nell1 in the developing cranial sutures in both human and
mouse induces craniosynostosis, the premature fusion of cranial sutures. This study
describes the characterization of Nell16R (102DSJ), a recessive, neonatal-lethal point
mutation in the mouse Nell1 gene, induced by N-ethyl-N-nitrosourea (ENU). The
generation and sequencing of the mouse full-length cDNA (2862 bp) revealed that the
Nell1 gene has an open reading frame of 2433 bp and encodes an 810 amino acid protein
which is highly homologous to human and rat NELL1. Nell16R has a T→A base change
that converts a codon for cysteine into a premature stop codon, resulting in severe
truncation of the predicted protein product and marked reduction in steady state levels of
the transcript. Immuno-histochemical analysis indicates that Nell1 is expressed in the
vertebral column and is involved in osteoblast and chondrocyte differentiation. In
addition to the expected alteration of cranial morphology, Nell16R mutants manifest
skeletal defects in the vertebral column and ribcage, revealing a hitherto undefined role
for Nell1 in signal transduction in endochondral ossification. Real-time quantitative RTPCR assays of 219 genes showed an association between the loss of Nell1 function and
reduced expression of genes for extracellular matrix proteins critical for chondrogenesis
and osteogenesis. Several affected genes are involved in the human cartilage disorder
known as Ehlers-Danlos Syndrome (EDS) and other disorders associated with spinal
curvature anomalies. Nell16R mutant mice are a new tool for elucidating basic
mechanisms in osteoblast and chondrocyte differentiation in the developing skull and
vertebral column and understanding how perturbations in the production of extracellular
matrix proteins can lead to anomalies in these structures. The characterization of Nell1
functions using the Nell16R mouse model may further provide insights into the pathology
of craniofacial defects like CS, cartilage diseases such as EDS as well as other bone and
cartilage diseases.
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CHAPTER 1
INTRODUCTION
Bone and cartilage constitute the primary structural support of the vertebrate
organism. The formation of bone (osteogenesis) and cartilage (chondrogenesis) are
complex processes involving several stages: a) commitment of the precursor cells, b) the
proliferation of the osteoprogenitor/chondroprogenitor cells, c) differentiation of
osteoblasts and chondrocytes and d) the formation of cartilage or a calcified bone matrix.
In the developing skull, calvarial bones are formed by intramembranous ossification, in
which mesenchymal cells differentiate into osteoblasts and the production of bone matrix
occurs directly without previous cartilage formation. Other bones in the body are formed
by endochondral ossification, in which mesenchymal cells differentiate into chondrocytes
and the formation of cartilage models occurs first, followed by replacement of the models
by bone. (Erlebacher et al. 1995; Hall et al. 2000). Normal bone formation involves a
delicate balance between proliferation, differentiation and apoptosis in osteoblasts and
chondrocytes. Disruption of this balance leads to many serious human birth defects and
diseases like craniosynostosis, osteochondrodysplasias, epiphyseal dysplasia, arthritis,
and osteoarthritis etc.
Understanding of the mechanisms underlying osteogenesis and chondrogenesis
has progressed considerably by studying mutations in humans and mice. Some of the
craniofacial and other bone diseases are due to known mutations in growth factors,
transcription factors and other proteins which are known to regulate osteoblast and
chondrocyte proliferation, differentiation and survival. However, the genetic and
molecular bases of many bone and cartilage diseases are still unknown, thus it is possible
that perturbations in other genes may be responsible for these disease processes.
In this dissertation research, a new mouse mutation generated at Oak Ridge
National Laboratory (ORNL) was characterized. This loss of function mutation was
associated with bone and cartilage defects. The characterization of genetic and functional
bases of this mutation will further contribute to the current understanding of the
mechanisms underlying osteogenesis and chondrogenesis.
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Large-scale mouse mutagenesis, conducted at ORNL, using the chemical
mutagen, N-ethyl-N-nitrosourea (ENU) has generated the mutations mapping to a small
segment of mouse chromosome 7, proximal to the pink-eyed gene (p) (Rinchik et al.
2002). One locus mutated in these experiments was designated as l7R6 and has yielded
eight recessive neonatally- lethal alleles. Homozygotes manifested abnormal head-shape
and body curvature of late gestation fetuses and neonates. High-resolution genetic and
molecular mapping indicated that l7R6 maps to a ~ 1 Mb interval homologous to a
segment of human 11p15 where the NELL1 gene is located. Initially six genes were
tested as candidates for the l7R6 locus. However, none of these genes were associated
with the skeletal defects and the gross and skeletal phenotypes observed in l7R6 mutant
mice. The preliminary molecular and phenotype analysis of four mutant alleles of l7R6
done in this study, along with the previously published data, further supported the
hypothesis that l7R6 is the Nell1 gene.
Earlier studies have demonstrated that Nell1 is a gene whose overexpression in
human and mouse leads to craniosynostosis (CS), premature closure of the cranial sutures
in the developing skull (Ting et al. 1999; Zhang et al. 2002). CS affects 1 in 3000 infants
and is one of the most common human congenital craniofacial deformities (Wilkie 1997;
Cohen 2000). In CS, constrained brain growth due to the cessation of skull growth leads
to a severe cranial dysmorphism, often resulting in increased intracranial pressure,
impaired cerebral flow, airway obstruction and impaired vision and hearing. A series of
major cranial surgeries in infants or young children are necessary to correct CS. (Wilkie
1997; Carver et al. 2002). Additionally, certain types of CS are associated with defects in
the limb and spine development (Anderson et al. 1996; Anderson et al. 1997). Zhang et al
(Zhang et al. 2002) further characterized the role of Nell1 in suture fusion by creating an
overexpressing transgenic mouse model. The transgenic mice exhibited CS and no
apparent defects in other organ systems. The results of their study suggest that
overexpression of Nell1 stimulates osteoblast differentiation at the growing fronts of the
calvarial bones leading to rapid mineralization and premature fusion of the sutures.
Another study by Zhang et al (Zhang et al. 2003) indicates that Nell1 modulates calvarial
osteoblast differentiation and apoptosis pathways during intramembranous ossification of
2

the developing skull. Moreover, both in vitro and in vivo studies showed that this gene
plays a role in osteoblast differentiation (Zhang et al. 2002; Zhang et al. 2003).
Additionally, Cowan et al (Cowan et al. 2006) reported that Nell1 accelerates
chondrocyte hypertrophy and endochondral bone formation within the distracted
maxillary suture. It also induced premature hypertrophy and increased apoptosis of
chondrocytes, which in turn leads to distortion of chondrocranium and subsequent cranial
deformity during mouse development (Zhang et al. 2006). The present study further
corroborates these reports; Nell1 is expressed in vertebral column and is involved in both
osteoblast and chondrocyte differentiation.
The preliminary molecular and phenotype analysis of four mutant alleles of l7R6
locus revealed that loss of function mutation at this locus leads to varying degrees of
skeletal defects in mutant mice ranging from mild to severe. In one of these l7R6 alleles,
designated as the 102DSJ stock, homozygote mutants exhibited marked cranial and
vertebral column defects and had severely reduced levels of Nell1 gene expression. As
such this severely affected allele became a focus of this dissertation research and the
Nell16R mutant allele was further characterized to study the consequences of Nell1
mutation in cranial and vertebral column development in mouse. The main goal of this
project is to determine the molecular/cellular and functional basis of the craniofacial and
axial skeleton (vertebral column) defects found in Nell16R allele.
Mutation in Nell16R was evaluated by examining gross morphological traits,
conducting detailed skeletal analysis and by using chemical stains specific for bone and
cartilage, and morphometric analysis of formalin fixed embryos. To characterize the
molecular basis of Nell16R mutation, expression profile of Nell1 gene during the mouse
development and impact of its mutation on the expression of Nell1 gene was investigated
by Northern blot, RT-PCR and immunohistochemistry. Additionally, the complete coding
sequence of the gene was sequenced along with identification of the Nell16R mutation. In
order to determine cellular functions of Nell16R, the expression of Nell1 in mutant fetal
vertebral columns and effects of its loss of function mutation on both chondrocyte and
osteoblast differentiation was examined by histochemical staining as well as
immunohistochemistry. In order to define the genes and pathways that are perturbed by
3

the Nell16R mutation, expression profile of 219 genes, which are associated with
craniosynostosis, osteogenesis/chondrogenesis and, growth and differentiation was
examined by Real-Time qRT-PCR analysis.
The results of this study suggested an association between the loss of Nell1
function and defects in the development of the skull and vertebral column. The Nell16R
mutants exhibit skeletal defects in the vertebral column and ribcage in addition to the
expected alteration in cranial morphology. These observations indicate that Nell1 may
play a yet undetermined role in endochondral ossification.
The impact of Nell1 on the formation of the vertebral column was a novel finding
and unexpected based on observations on the overexpressing transgenic mouse model.
This study also demonstrated that in the Nell16R mutation, there is a reduced expression
of numerous extracellular matrix proteins that are critical for chondrogenesis and
osteogenesis. Several affected genes are implicated in the pathophysiology of human
cartilage/connective tissue disorder, Ehlers-Danlos Syndrome (EDS) and other disorders
associated with skeletal defects in the vertebral column. EDS, a severe cartilage defect,
which affects 1 in 5000 individuals, is characterized by hyperextensibility of the skin and
extreme flexibility of joints (Beighton et al. 1998; Mao et al. 2001). Individuals with EDS
do not have the ability to make certain components of the connective tissue, particularly
fibrillar collagens, or they have defective regulation of collagen synthesis and deposition
(Mao et al. 2001; Mao et al. 2002). One particular form of EDS, EDS-type VI is
characterized by abnormal curvature of the spine, hypotonia, joint laxity and ocular
fragility (Beighton et al. 1998; Mao et al. 2001). The data generated from this study
suggests that, in addition to its role in intramembranous ossification in the skull, Nell1
plays a critical role in endochondral ossification and chondrogenesis in the developing
vertebral skeleton. The characterization of Nell1 functions using the Nell16R mutation is a
unique opportunity to further elucidate the basic mechanisms of osteogenesis and
chondrogenesis. It will provide insights into the pathology of craniofacial defects like CS,
as well as other bone and cartilage diseases such as EDS.

4

CHAPTER 2
LITERATURE REVIEW
VERTEBRATE SKELETON

Forget the great human heart and the brain, the eyes that see sweeping vistas, the lips
that declare, “I am”. The real thing standing between us and the primordial ooze is the
human skeleton. Built of 206 bones, the skeleton is a living cathedral of ivory vaults, ribs
and buttresses- a structure at once light and strong, flexible and firm. (Angier 1994).
The vertebrate skeleton, which is composed of cartilage and bone, develops from
cells from three embryonic lineages: neural crest, paraxial mesoderm and lateral plate
mesoderm. Neural crest cells give rise to most of the craniofacial skeleton. The axial
skeleton consisting of the vertebrae and ribs is derived from the paraxial mesoderm
(somites) and the appendicular (limb) skeleton originates from the lateral plate
mesodermal cells. Cells from these lineages migrate to the sites in the developing embryo
where future skeletal elements will emerge and form mesenchymal
osteogenic/chondrogenic condensations and differentiate into specialized cells called the
osteoblasts and chondrocytes (Hall et al. 1995) (Fig.2.1).
BONE: Bone is a highly complex and specialized tissue that forms a supporting
framework for the vertebrate body. It supports and protects many delicate organs in the
body, supports hematopoiesis in the bone marrow and participates in calcium
homeostasis (Cohen 2006). Bone is made up of osteoblasts, which are responsible for
secreting the matrix. Once these cells fully differentiate and are surrounded by calcified
matrix, they become quiescent and are known as osteocytes. Bone is composed of an
organic matrix (95% COL-1, 5% proteoglycans and non-collagenous proteins) that is
strengthened by inorganic salts (mainly calcium phosphate in the form of hydroxyapatite)
(Anderson, 1995). There are two varieties of bone tissue, cortical and cancellous. Cortical
or compact bone is dense and extremely hard due to the densely packed collagen fibrils
5
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Figure. 2.1: Embryonic Cell Lineages and Early Steps in the Development of
Vertebrate Skeleton. Osteoblasts deposit bone matrix while chondrocytes form cartilage. A third cell
type of the skeletal system, called osteoclasts resorb bone. Osteoblasts and chondrocytes originate from
mesenchymal cells whereas osteoclasts arise from the hematopoietic system (Cohen 2006).
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that form concentric lamellae. The blood vessels in the cortical bone occupy small tube
like spaces called Haversian canals. Each canal is surrounded by several lamellae, and
forms a cylindrical block of bone called a Haversian system. The diaphysis (shaft) of
typical long bones such as femur and humerus consists of a thick walled hollow cylinder
of compact bone and a central marrow cavity. Cortical bone provides protection and
mechanical support. Cancellous bone is light and spongy and consists of a three
dimensional lattice of bony spicules or trabeculae that create many large
intercommunicating spaces that are filled by bone marrow. It lies deep within the cortical
bone and provides metabolic functions. The two forms of bone merge (abrupt transition)
into one another without a sharp boundary. (Gillison 1962; Fawcett 1994).
CARTILAGE: Cartilage is a unique connective tissue found in the structures of certain
organs that forms a close association with the bone and plays numerous important roles
during vertebrate prenatal and postnatal development. Cartilage provides a template for
the developing bones, a structural support for the developing embryo, factors for
postnatal growth of the skeleton, cushion for the joints, flexibility to facial structure, and
repair mechanisms for fractured bones. Furthermore, cartilage in airways, joints and ears
are crucial for breathing, locomotion and hearing because it allows for movements
without interfering with function. (Shum et al. 2002; Lefebvre et al. 2005).
Cartilage is made up of chondrocytes, which occupy small cavities called lacunae
within the extracellular matrix they secrete. There are three types of cartilage: hyaline,
elastic and fibrocartilage. Hyaline cartilage forms the temporary cartilage of the skeletal
system and is gradually replaced by bone. In fully developed bones, hyaline cartilage
persists as a covering for the articular surfaces. This articular cartilage allows for the
smooth movements of joints and acts as a shock absorber. Ribs are attached to the
sternum by hyaline cartilage and the cartilage increases the mobility and the flexibility of
the thorax, which is crucial for respiration. Hyaline cartilage is also found in the
respiratory passages such as trachea, bronchi, larynx and tip of the nose. Elastic cartilage
is more flexible and resilient than the other cartilages. It is only found in a few parts of
the body where flexibility is required, as in the pinna of the ear, auditory tube, epiglottis
7

and parts of the larynx. Fibrocartilage is always found in conjunction with hyaline
cartilage or other fibrous tissue. It is much less flexible and resilient than hyaline
cartilage but is very dense, tough and resistant to stretching. It is associated with the
capsules and ligaments of joints such as tempro-mandibular, sterno-clavicular, shoulder,
hip and knee joints. Intervertebral discs are made up of fibrocartilage and the cartilage
allows limited compression or torsion and allows limited movement between adjacent
vertebrae. The discs also act as shock absorbers preventing excessive jarring of the spine
and head. (Gillison 1962; Fawcett 1994).

SKELETOGENESIS
The formation of bone (osteogenesis) and cartilage (chondrogenesis) are complex
processes involving several stages: a) commitment of precursor cells, b) proliferation of
the osteoprogenitor/chondroprogenitor cells, c) differentiation of osteoblasts and
chondrocytes, and d) the formation of cartilage or a calcified bone matrix. The earliest
event in skeletal morphogenesis is the migration of mesenchymal cells to the locations of
future skeletal elements, where they form dense condensation at the sites of future bones.
Condensations are either osteogenic or chondrogenic, depending on the skeletal elements
they initiate (Erlebacher et al. 1995; Hall et al. 2000). This event is followed by
differentiation to chondrocytes or osteoblasts within the condensation. The subsequent
growth during the organogenesis phase generates cartilage models (anlagen) of future
bones as in limb bones or membranous bones as in the cranial vault. The craniofacial
skeleton is constructed by membranous ossification, wherein differentiation of
mesenchymal cells to osteoblasts and the production of bone matrix occurs directly
without cartilage formation (Erlebacher et al. 1995; Hall et al. 2000) (Fig. 2.2A). The
axial and limb skeletal systems are developed by endochondral ossification, where
differentiation of mesenchymal cells to chondrocytes, and formation of cartilage model
occurs first, followed by the replacement of the models by bone (Fig. 2.2B).

8

Figure 2.2: Intramembranous and Endochondral Ossification. (A). Mesenchymal cells
from neural crest differentiate into osteoblast and production of bone matrix occurs directly without
formation of cartilage. (B). Mesenchymal cells from somites differentiate into chondrocytes to form a
cartilage model (anlagen). In the center of the anlage chondrocytes mature, hypertrophy and begin to
express high levels of Vascular Endothelial Factor (VEGF), which facilitates invasion of capillaries into the
anlage with subsequent recruitment of osteoblasts. Osteoblasts produce bone matrix to generate the collar
of bone and growth plates (green area). Hypertrophic cartilage is subsequently degraded and eventually
replaced by cancellous bone and bone marrow. [Modified from ((Zelzer et al. 2003)].
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INTRAMEMBRANOUS OSSIFICATION: In the developing skull, calvarial bones,
mandibles, and clavicles are formed by intramembranous ossification (Zelzer et al. 2003).
Formation of these bones involve the migration of undifferentiated mesenchymal cells
from the neural crest into areas destined to become bone, where they condense and
proliferate in response to the signals from the underlying neural tissue. Molecular signals
from growth factors like Bone Morphogenetic Proteins (BMPs), Fibroblast Growth
Factors (FGFs), Epidermal Growth Factor (EGF), Insulin like growth factors (IGFs) and
transcription factors trigger differentiation into osteoprogenitor cells and subsequently
into osteoblasts. Osteoblasts secrete a mineralized matrix in the ossification centers. At
the end of the formation period, osteoblasts die by apoptosis or are embedded in the
matrix, becoming osteocytes, which then undergo apoptosis at the end of their life. The
flat calvarial bones of the skull grow towards each other from the primary ossification
centers and meet at sutures. Then the calvarial bones grow at the sutures in concert with
the expanding brain. The center of the suture contains proliferatory pre-osteoblast
population, which eventually differentiates and moves toward adjacent bone surfaces,
becoming osteoblasts. (Wilkie 1997; Zelzer et al. 2003).
Based on morphological and histological studies, osteoblastic cells in vivo are
believed to follow a linear developmental progression from proliferating osteoprogenitors
to proliferating pre-osteoblasts to mature osteoblasts to osteocytes (Stein et al. 1993) (Fig.
2.3). As the osteoblasts progress through these stages, there is a sequential expression of
cell growth, tissue and stage specific genes. During the proliferative stage, the
prominently expressed genes are FGF, EGF, Platelet Derived Growth Factor (PDGF) and
IGFs. During the differentiation process, specific genes and extracellular matrix (ECM)
biosynthesis associated factors, like BMPs, Transforming growth factor-β (TGF-β), FGF3 and type I collagen (COL-1) are expressed (Stein et al. 1993). Alkaline phosphatase
(AP) and Bone Sialoprotein (BSP) expression are relatively high during the matrix
modulation stage. These differentiation-specific genes that are associated with maturation
and organization of the bone ECM are essential for preparing the matrix for
mineralization. During bone mineralization, osteopontin (OPN) and osteocalcin (OCN)
are maximally expressed (Stein et al. 1993). Mineralization of ECM marks the final
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Figure 2.3: Regulation of Osteoblast Proliferation and Differentiation by Growth
Factors and Transcription Factors. See text for details. [Modified from (Komori 2002)].
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phase of osteoblast phenotype development.
ENDOCHONDRAL OSSIFICATION: Embryonic cartilage can either remain as
permanent cartilage such as hyaline cartilage on the articular surfaces of bones, elastic
cartilage in the ear, or fibrocartilage in intervertebral discs or it can provide a template for
the bones through the process of endochondral ossification. Majority of the bones (axial
and appendicular skeleton) in the body except calvarial bones, clavicles and mandible are
formed by endochondral ossification in which mesenchymal cells differentiate into
chondrocytes and the formation of cartilage models (anlagen) occur first, followed by
replacement of the models by bone (see Fig.2.2B). (Komori 2002; Cohen 2006).
It is a multi-step process that involves two successive cell-differentiation
processes (Fig. 2.4). Undifferentiated mesenchymal cells from somites and lateral plate
mesoderm migrate to the sites of future bones and form chondrogenic condensations, and
under the control of SOX family of transcription factors, these mesenchymal cells
differentiate first in to COL-2A producing pre-chondrocytes and then into immature
chondrocytes that proliferate until the general shape of the future bone is established.
This cartilage template (anlagen) is eventually replaced by bone. The type of skeletal
elements that form from the immature chondrocytes depends on several transcription
factors. OSF-2/RUNX2 (and possibly OSX) induces the formation of replacement
cartilage while continued action of SOX9 (and possibly SOX5/SOX6) produces persistent
cartilage. These COL-2B producing (chondrocyte specific collagen) immature
chondrocytes further proliferate under the influence of FGF-3, mature and then arrest in
their cell cycle. The mature chondrocytes undergo morphological and gene expression
changes. COL-1 is turned off and COL-10 is turned on as cells differentiate further into
hypertrophic chondrocytes. The latter express predominantly COL-10 and synthesize a
cartilaginous matrix that eventually calcifies. At the same time these terminally
differentiated hypertrophic chondrocytes start expressing a high level of vascular
endothelial growth factor (VEGF), a growth factor needed for the invasion of blood
vessels into the cartilage and undergo apoptosis. The invading blood vessels bring
chondroclasts (which degrade mineralized chondrocyte matrix), osteoblasts and
13
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Figure 2.4: Regulation of Chondrocyte Proliferation and Differentiation by Growth
Factors and Transcription Factors. See text for details. [Modified from (Komori 2002)].
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osteoclasts into the ossification center. The cartilaginous matrix is then degraded and
eventually replaced by a bone synthesized by the osteoblasts. In the developing long
bones, the primary ossification centers split into opposite growth plates in which the
maturation of cartilage and subsequent bone formation continues. The growth plate
cartilage is responsible for the longitudinal bone growth during postnatal life and as the
bones grow, the increasing space between the growth plates becomes filled with bone
marrow (see Fig.2.2B). (Ducy et al. 1998; Shum et al. 2002; Zelzer et al. 2003).
Development of Axial Skeleton: The vertebrate axial skeleton consists of the skull base,
vertebral column and ribcage. The vertebral column is the primary and most important
component of the axial skeleton that arises via endochondral ossification. This skeletal
structure not only supports and stabilizes the vertebrate organism but also permits various
types of mobility. The vertebral column is comprised of a series of anatomical structures
called the vertebrae, which are arranged in craniocaudal pattern. There are seven cervical,
twelve thoracic and five lumbar vertebrae in humans (Sofaer 1985). There are at least
twenty-five intervertebral discs between the adjacent vertebrae, which are made up of
three integrated tissues: the gelatinous nucleus pulposus, fibrous annulus fibrosus, and the
cartilage end plate. Intervertebral discs provide stability and flexibility to the spine and
protect it by absorbing and distributing physical and mechanical loads (Humzah et al.
1988).
Axial skeleton morphogenesis requires a coordinated series of cellular and
molecular events, which are regulated by transcription factors like MSX-1 and -2, PAX1,
3, and 9 and growth factors like FGF-8, BMP-4 and -2 (Watanabe et al. 1998; Peters et
al. 1999; Pourquie 2003). Vertebral column development starts with the formation of
somites from the unsegmented paraxial mesoderm on both sides of the neural tube. The
somites then compartmentalize, differentiate and de-epithelialize to generate
dermomyotomes and sclerotomes. Dermomyotomes give rise to appendicular and axial
musculature while sclerotomes form the skeletal elements of the vertebral column and
ribs. The densely packed cells at the anterior sclerotomal region give rise to intervertebral
discs while less dense areas between intervertebral disc regions form the cartilage model
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(anlage) for vertebral bodies. The sclerotome cells then migrate ventrally and medially,
ultimately surrounding the notochord to form the perichondral tube. This tube eventually
becomes segmented and gives rise to vertebral bodies and intervertebral discs. During the
6th week of gestation pre-vertebrae are converted to cartilage and the endochondral
ossification begins at the 8th week. (Christ et al. 1998; Peters et al. 1999; Giampietro et al.
2003). During the vertebral column development, somitogenesis is regulated by a
segmentation clock, a timing mechanism responsible for the periodic production of
somites by periodic expression of ‘cyclic’ genes (related to Notch pathway) and FGF
signaling wave front, which in turn are regulated by Wnt and Notch signaling (Pourquie,
2003). Abnormalities in the genes controlled by segmentation clock are known to cause
severe defects during vertebral column development and are similar to pathological
conditions like scoliosis (Giampietro et al. 2003; Sparrow et al. 2006). Currently there is
a wealth of information available on early patterning process (embryonic segmentation of
vertebral column), in terms of patterning genes, growth factors and transcription factors
that are involved in the vertebral column development. However, the events, which occur
later during the development of vertebral column like chondrogenesis and osteogenesis
and the factors and pathways that regulate these processes, are not clearly understood.

MOLECULAR BASIS FOR BONE AND CARTILAGE FORMATION
Skeletogenesis is a very complex process, which is regulated by a series of
molecular events involving many transcription factors, growth factors and ECM proteins.
Importance of transcription factors like OSF-2/RUNX2, MSX2 and growth factors like
FGFs, BMPs, TGF-β along with ECM proteins like collagens, matrilins, tenascins,
thrombospondins and signal transducers like PKC, in both osteogenesis and
chondrogenesis has been demonstrated by studies conducted in both human and mouse
(Pacifici et al. 1993; Prockop et al. 1995; Jena et al. 1997; Komori et al. 1997; Wilkie
1997; Liu et al. 1999; Chapman et al. 2001; Hay et al. 2001; Komori 2002; Rosado et al.
2002; Marie 2003; Hankenson et al. 2005; Bandyopadhyay 2006; Desai et al. 2006).
NELL1 is a relatively new gene with osteoinductive properties that is rapidly emerging as
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a new player in the field of osteogenesis and chondrogenesis. All the proteins mentioned
above along with NELL1 are involved in the signaling pathways that are utilized in
osteogenesis/chondrogenesis and NELL1 is known to be regulated (directly or indirectly)
by these transcription and growth factors and it in turn regulates some of these proteins.
TRANSCRIPTION FACTORS: There are several transcription factors (TFs) that play
central regulatory roles during bone and cartilage development. The expression of these
factors in osteoblasts and chondrocytes coincides with the sequential development of
these cells. Proliferation-specific TFs like MSX-2 and TWIST are expressed in preosteoblasts; and MSX-2, SOX-5, -6, and -9 in pre-chondrocytes, while RUNX-2 and
Osterix (OSX), which are associated with terminal differentiation, are expressed in
mature osteoblst.
Osteoblast specific factor (Osf-2): OSF-2, also known as AML-3 or core-binding
factor-1 (CBFA-1) or RUNX2, is a transcription factor that belongs to the Runt family of
transcription factors that is essential for bone formation during embryogenesis. It is a
master transcription factor that is necessary for all stages of bone formation (Ducy 2000).
Osf-2/Runx2 is expressed in mesenchymal condensations (osteochondroprogenitor cells)
during the early development on embryonic day 12 (E12). From mid-gestation (E14) Osf2/Runx2 expression becomes progressively stronger in the cells of osteoblast lineage
(Karsenty 2001). OSF-2/RUNX2 is crucial for osteoblast development from mesenchymal
stem cells and maturation into osteoblasts by regulating the transcription of several target
genes. Multiple OSF-2/RUNX2 binding sites were found in promoter regions of all the
major genes expressed by osteoblasts, such as COL-1 and 2, BSP, OPN and OCN (Ducy
2000) and also craniosynostosis-associated gene, NELL1 (Truong et al. 2007). All these
bone matrix proteins are sequentially expressed during osteoblast differentiation and bone
matrix mineralization.
Although the level and pattern of OSF-2/RUNX2 transcriptional indicated its
involvement in osteoblast differentiation, human genetic and Osf-2/Runx2 knockout
mouse studies confirmed that it is an essential factor for osteoblast differentiation. Osf17

2/Runx2-/- mice die at birth and lack both endochondral and intramembranous
ossification. These mice completely lack osteoblasts, are devoid of mineralized bone and
the entire skeleton consists of only cartilage. The skeletal structures like calvarial bones
and clavicles are missing. Additionally, the mice do not express certain ECM proteins
like Bsp, Opn, and Ocn, which are known biomarkers for osteoblast differentiation
(Komori et al. 1997; Otto et al. 1997). Human mutations in OSF-2/RUNX2 cause
cleidocranial dysplasia (CCD), an autosomal dominant disease characterized by the
defects in both endochondral and intramembranous bone formation, such as absence of
clavicles, persistent open fontanelles, supernumerary teeth, and short stature (Lee et al.
1997). Mice with heterozygous mutation in Osf-2/Runx2 showed a phenotype similar to
CCD in humans (Mundlos et al. 1996).
As mentioned above Osf-2/Runx2 is expressed early during the development
(E12.5) in osteochondroprogenitor cells in mice. However, from E12 to birth, its
expression in cartilage is restricted to prehypertrophic and hypertrophic chondrocytes
(Karsenty 2001). This spatio-temporal pattern of OSF-2/RUNX2 expression along with its
transcriptional control of COL-10 gene (chondrocyte differentiation marker) suggests that
it may be involved in chondrocyte terminal differentiation. These findings were further
confirmed by the observation that in Osf-2/Runx2-/- mice, the entire skeleton is composed
of cartilage, chondrocyte differentiation is severely affected in most of the skeleton and
no Col-10 expression and vascular invasion of the cartilage is detected (Inada et al.
1999). Forced expression of Osf-2/Runx2 driven by Col-2 or Col-10 promoter which
target chondrocytes in these mice, partially rescued Osf-2/Runx2 deficient mice by
inducing hypertrophic chondrocyte differentiation (Takeda et al. 2001).
OSF-2/ RUNX2 also plays a role in postnatal bone formation. It is expressed in
mature postnatal osteoblasts and over-expression of dominant negative Osf-2/Runx2 in
these cells results in osteopenia, with decreased expression of Col-1 and -2, Bsp, Opn,
and Ocn (Ducy et al. 1999). Furthermore, over-expression of Osf-2/ Runx2 in adult aging
mice resulted in severe osteopenia due to impaired osteoblast maturation and increased
bone formation as well as bone resorption (Geoffroy et al. 2002). Transcription of
OSF2/RUNX2 is regulated by many growth factors and transcription factors that are
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known to play a critical role in skeletogenesis. It is positively regulated by BMPs, FGFs,
retinoic acid and down-regulated by1, 25(OH2) D3 and TNF and OSF-2/RUNX2 itself
(Lee et al. 2000; Komori 2002). Depending on the cell type it is positively or negatively
regulated by TGF. RUNX2 forms a heterodimer with transcription cofactor CBF-β (core
binding factor β) and interacts with many other transcription factors (Smad, C/EBP and
Ets) and cofactors (Rb). Additionally it is positively regulated by the transcription factor,
MSX2. (Komori 2002).
Msx-2: MSX-2 is a member of a small family of homeobox containing genes related to
the muscle-segment (msh) gene in Drosophila (Liu et al. 1999). In the developing
vertebrate, it is expressed in several tissues and is known to mediate craniofacial and limb
morphogenesis (Bendall et al. 2000). In mice, Msx-2 is expressed during critical stages of
neural tube, neural crest, teeth and skull and facial bone development (Foerst-Potts et al.
1997). It is expressed in the developing calvaria and is involved in osteoblast
proliferation, differentiation and function. Several studies show that MSX-2 downregulates the differentiation in calvarial osteogenic cells and maintains them in a
proliferative state. This in turn increases the pool of proliferative osteogenic cells and
ultimately increases calvarial bone growth (Dodig et al. 1999). Forced expression or
over-expression of Msx-2 in mouse calvarial osteoblast enhanced calvarial bone growth.
(Dodig et al. 1999; Liu et al. 1999). Gain-of-function mutation in the human MSX-2 gene
causes an autosomal dominant disorder, Boston type craniosynostosis. Liu et al (1999)
postulated that MSX-2-mediated craniosynostosis arose by transient retardation of
osteogenic cell differentiation in developing cranial suture. Msx-2-deficient mice exhibit
a marked delay in the ossification in calvarial bones, calvarial foramen and overall
decrease in bone volume (Satokata et al. 2000). This phenotype results from decreased
proliferation of osteoprogenitors at the osteogenic front in cranial sutures and closely
resembles the phenotype associated with human haploinsufficiency in parietal foramina
(Wilkie et al. 2000). Additionally, Msx-2-/- mice also have defects in cartilage and
endochondral bone formation. Axial and appendicular skeletal lengths were reduced;
mutants had reduced number of osteoblasts and chondrocytes at the epiphysis. In mutant
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long bones, postnatal expression of bone differentiation marker genes like Bsp, Osf2/Runx2 and Ocn were also reduced (Satokata et al. 2000). These reports demonstrate
that MSX-2 is required for both chondrogenesis and osteogenesis and acts upstream of
OSF-2/RUNX-2.
EXTRACELLULAR MATRIX (ECM) PROTEINS: Most of the cells in multicellular
organisms are surrounded by a complex network of macromolecules that make up the
extracellular matrix. The ECM provides structural support for the cells, tissues and
organs, facilitates cell communication and acts as a physical barrier or selective filter to
soluble molecules. In addition, macromolecules in the ECM regulate the behavior of the
cells that contact them and thereby influence their development, survival, migration,
proliferation, differentiation, shape and size. Although cells in connective tissue are
surrounded by ECM, its composition and spatial relationship with cells differ between
tissues (Alberts 1994). ECM is a complex network of macromolecules like
glycosaminoglycans (hyaluronan, heparin sulfate, keratin sulfate, chondrotin sulfate and
dermatan sulfate), proteoglycans (aggrecan, decorin, dyndecans, chad, proteoglycan 4),
glycoproteins (thrombospondin, tenascin), fibrous proteins (collagen, elastin, fibronectin
and laminin), and non-collagenous proteins and polysaccharides. These macromolecules
are mainly produced by fibroblasts in the matrix. However, in certain types of connective
tissues, such as cartilage and bone, they are secreted by chondrocytes and osteoblasts.
Aggregates of collagen fibers and proteoglycans provide the structural base for ECM
architecture. (Alberts 1994).
Collagens: The collagens are a family of fibrous ECM proteins that play a role in
maintaining the structural integrity of various tissues. They are the most abundant
proteins in animals, consisting of 25% of the total protein mass in these organisms.
Collagens also play a role in the early development and organogenesis, chemotaxis, cell
attachment and platelet aggregation (Kivirikko 1993). They are secreted by both
connective tissue cells and other cell types and are present in most tissues and especially
abundant in cartilage, bone, skin, tendons and ligaments. So far, at least 27 genetically
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distinct collagen proteins have been identified (Kivirikko 1993; Myllyharju et al. 2004).
Collagens can be classified into subgroups on the basis of their particular structural
features. These groups are: 1. Fibrillar collagens (fibril forming collagens) such as COL I,
II, III, V and XI. These are the main collagens found in connective tissue. COL I is the
principal collagen of skin and bone. 2. Collagens that form network-like structures such
as COL IV, VIII and X. 3. Fibril-associated collagens with Interrupted Triple-Helices
(FACIT) such as COL IX, XII, XIV, XVI and XIX. These collagen types are known to
associate with the fibrous collagen. 4. Collagens with transmembrane domains, types XIII
and XVII. 5. Collagens that form anchoring fibrils for basement membrane, type VII. 6.
Beaded filament forming collagen. Type VI. (Kuivaniemi et al. 1997).
Mutations in collagen genes cause a variety of human diseases such as
Osteogenesis imperfecta, some types of Ehlers-Danlos syndrome, Chondrodysplasias,
some forms of osteoporosis and osteoarthritis, arterial and intracranial aneurisms and
epidermolysis bullosa (Prockop et al. 1995).
Collagen ii (col-2): COL-2 is the major fibrous collagen found in cartilage and
constitutes 80-90% of the collagen content of the cartilage matrix. It is also found in
related tissues such as the intervertebral disc, vitreous humor of the eye and the inner ear.
It is preferentially expressed in the perichondrium, in pre-cartilage limb mesenchyme in
chicks and in non-cartilage tissues. It is expressed in spatio-temporal pattern during the
development of craniofacial, heart, brain, skin, skeletal muscle and nucleous pulposus of
the intervertebral disc. (Thorogood et al. 1986; Nah et al. 1991; Sandell et al. 1991;
Helminen et al. 1993). Several studies indicate that mutations in COL-2A cause a number
of diseases of joints and skeleton. These include several chondrodysplasias, a
heterogeneous group of disorders that are characterized by malformations of cartilaginous
structures and degenerative changes of joints. Mutation in human COL-2A1 gene caused
osteochondroplasia in transgenic mice and they exhibited flattened vertebral bodies,
dysplastic changes in long bones, osteoarthritis in their joints, degenerated intervertebral
discs with altered histological structures, and these changes were more severe in mice
with no murine Col-2A1 allele (Sahlman et al. 2004). Thus it is an important component
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of the cartilage matrix that is formed during skeletogenesis and it especially plays a
critical role in endochondral ossification (Helminen et al. 1993).
Collagen v (col-5): COL-5 is a minor fibrillar collagen, which participates in the
formation of fibrillar collagen network and the regulation of fibrillogenesis. It is
expressed in a variety of tissues such as bone, cornea, placenta and fetal membranes
(Malfait et al. 2005). It occurs as a heterotrimer of three different polypeptide chains, α1
(Col-5A1), α2 (Col- 5A2) and α3 (Col-5A3). It can form two forms of heterotrimers
(α1)2α2 and α1α2α3 or as (α1)3 homotrimers. It regulates fibrillogenesis by coassembling with COL-1 (Malfait et al. 2005).
Collagen-5a1 (col-5a1): It is expressed in adult skin, tendon and in
calvaria and long bones but not in the cartilage of the developing mouse embryo.
Mutations in the COL-5A1 and COL-5A2 genes result in classic EDS (type I and II) and
in one third of patients, the disease is caused by mutant non-functional COL-5A1 allele
(Schwarze et al. 2000; Malfait et al. 2005). Hence the mutation in COL-5A1 leads to
classical EDS, which is caused by aberrant fibrillogenesis.
Collagen-5a3 (col-5a3): It is highly expressed in mammary gland,
placenta, uterus, fetal, heart and lung, moderately in adult heart and brain. In addition, it
is primarily expressed in epimysial (connective tissue) sheaths of developing muscles and
within nascent ligaments adjacent to forming bone and joints during the development.
Due to its expression in epimycium, it has been speculated that altered expression of
COL-5A3 might result in some muscle myopathies. (Imamura et al. 2000). Based on its
expression in developing tendons and joints and its ability to form heterotrimers with
COL-5A1 and -A2 chains, it has been suggested that altered expression of COL-5A3 may
account for at least some cases of classical EDS in which COL-5A1 and -A2 have been
excluded (Imamura et al. 2000). Defects in COL-5A3 may also contribute to at least
some cases of hypermobility type of EDS, which is characterized by chronic diffuse
muscle pain along with classical EDS symptoms (Imamura et al. 2000).
Collagen vi (col-6): COL-6 belongs to a subtype of bead forming collagens and
assembles into beaded microfibrils in cartilage and in other tissues such as aorta,
placenta, uterus, intervertebral disc, tendon, cornea, muscle, liver and kidney (Thomas et
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al. 1994). These microfibrils localize close to cells, nerve, blood vessels, and large
collagen fibrils and may be involved in the anchoring process. It is known to bind cells
via COL-1, decorin and hyaluronan (which in turn binds to cartilage proteoglycan). This
binding activity suggests that COL-6 may be involved in cell migration, differentiation,
growth, remodeling process of connective tissue and embryonic development. (Bidanset
et al. 1992; Kielty et al. 1992). It is expressed in a spatio-temporal manner during mouse
embryogenesis; expression was detected in 10.5 day embryos, in branchial arches, large
blood vessels and cephalic mesenchyme. By 16.5 days Col-6A expression increased in
joints, intervertebral discs, perichondrium, periostium, dermis skeletal muscle and heart
valves (Marvulli et al. 1996).
Increased COL-6 collagen synthesis and disposition has been detected in several
fibrotic diseases, osteoarthritis and patients with cutis laxa, which is characterized by loss
of elasticity in the skin (van der Rest et al. 1991). A recent study indicates COL-6A1 on
chromosome 21 as the locus of ossification of the posterior longitudinal ligament
(OPLL). OPLL is a subset of disease, characterized by ectopic ossification in the spinal
ligaments, is a common disorder that affects elderly population in eastern Asia and is a
leading cause of spinal stenosis in Japan (Tanaka et al. 2003).
Collagen x (col-10): COL-10 belongs to a subtype of network-forming collagens.
This homotrimeric, developmentally regulated collagen has a very restricted pattern of
distribution. It is expressed only by the hypertrophic chondrocytes transiently during
endochondral bone formation, and such as a tissue specific expression makes COL-10 an
only known molecular marker specific for chondrocyte differentiation (Thomas et al.
1994). Transcription factor OSF-2/RUNX-2 is required for differentiation of the
mesenchymal stem cells into osteoblast lineage (Komori et al. 1997) and for chondrocyte
differentiation during endochondral ossification (Enomoto et al. 2000), and multiple Osf2/Runx-2 binding sites have been identified within the promoter region of the human,
mouse, and chick Col-10 (Zheng et al. 2003). Decreased Col-10 expression and altered
chondrocyte hypertrophy was detected in Osf-2-2/Runx-2 heterozygous mice and no Col10 expression was detected in Osf-2/Runx-2 null mice (Zheng et al. 2003), suggesting
Col-10 is a direct transcriptional target of Osf-2/Runx-2 during chondrogenesis. Mutation
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in human COL-10 is associated with a cartilage disorder, Schmid metaphyseal
chondroplasia (SMCD) (Warman et al. 1993). The Col-10-null mice exhibit growth plate
compressions partially resembling SMCD (Kwan et al. 1997).
Collagen xii (col-12a1): COL-12A1 belongs to subgroup FACIT collagens. It is
expressed in embryonic tendon and skin, periodontal ligament, and perichondrium at the
articular surface and around cartilage canals. Its functions are not clear but evidence
suggests that COL-12A1 interacts with COL-1 (van der Rest et al. 1991; Thomas et al.
1994).
Collagen xvi (col-15a1) and collagen xviii (col-18a1): COL-15A1 and COL18A1 together form a distinct not yet named subgroup of non-fibril forming collagens.
COL-18A1 is the precursor of endostatin (anti-angiogenic factor) and the corresponding
fragment in COL-15A1 has also been shown to have anti-angiogenic activity
(Ramchandran et al. 1999; Sasaki et al. 2000). COL-15A1 is expressed in many tissues
including kidney, lungs, most capillaries, heart and skeletal muscle (Hagg et al. 1997).
COL-18A1 is expressed in several tissues including liver, lung, kidney, and eye (Oh et al.
1994). Col15A1 provides mechanical stability to skeletal muscle cells and micro vessels
(Eklund et al. 2001). COL-18A1 functions as an endogenous inhibitor of angiogenesis
and tumor growth and also known to play a critical role in maintenance of the retinal
structure and in neural tube closure (Sertie et al. 2000).
Collagen xvii (col-17a1): COL-17A1 belongs to a subclass of collagens with a
transmembrane domain, and is a structural component of hemidesmodomes (multiprotein
complexes that mediate the adhesion of epidermal keratinocytes to the underlying
basement membrane) and is expressed in stratified squamous epithelium (Diaz et al.
1990; Li et al. 1993). Mutations in COL-17A1 cause generalized atrophic epidermolysis
bulbosa, a condition characterized by universal alopecia and atrophy of skin (Gatalica et
al. 1997).
Non-Collagenous Extracellular Matrix Proteins: The non-collagenous proteins like
glycosominoglycans and proteoglycans together form hydrated gel-like substance and
occupy a large volume of extracellular space. This fibrous protein embedded gel-like
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substance not only helps to resist the comprehensive force on the matrix but it also
permits the diffusion of nutrients, metabolites and hormones. While fibrous proteins like
collagens and elastin provide tensile strength and elasticity to the tissues, noncollagenous proteins help cells in the tissue to carry out many of their biological
functions. They facilitate cell adhesion, migration, differentiation and signaling. Several
cell surface proteoglycans act as co-receptors for collagens, growth factors and other
ECM proteins. (Alberts 1994). Some of the following non-collagenous proteins are
associated with bone and cartilage development, cell growth and differentiation, cell
adhesion and communication.
Matrilins: Matrilins belong to the superfamily of proteins with von Willebrand
factor type A-like (vWF- A) modules. Matrilins are adapter proteins that form both
collagen-dependent and collagen-independent filamentous networks (Mates et al. 2004).
The matrilin family has four members, each containing one or two vWF-A domains, a
variable number of EGF-like domains and a coiled coil c-terminal domain. vWF-A
domains are known to mediate interactions with other proteins and are implicated in
oligomerization, formation of macromolecular networks, cell adhesion and spreading
(Jackson et al. 2004). Matrilins interact with collagens and proteoglycans. Matn-1 binds
to aggrecan (Hauser et al. 1996) as well as to Col-2 in vivo (Winterbottom et al. 1992)
and is also known to bind integrin α1β1, suggesting its involvement in cell adhesion and
spreading (Makihira et al. 1999). Matrilin (MATN) -1 associates with cartilage
proteoglycans in addition to being a component of both collagen- dependent and –
independent fibrils (Deak et al. 1999). Furthermore, MATN-1, -3, and -4 are associated
with COL-6 microfibrils in rat chondrosarcoma tissue and connect these fibrils to
aggrecan and COL-2 (Wiberg et al. 2003). While MATN -1, -2, -3, and -4 are expressed
in cartilaginous tissue; only MATN-2 and -4 are expressed in a variety of ECMs
including non-skeletal tissues (Deak et al. 1999).
MATN-3 is a monomeric protein with only one vWFA domain followed by four
EGF-like domains and a C-terminal coiled -coil domain. MATN-3 is known to form
homotrimers via coiled-coil domain and mixed trimers and tetramers of MATN-3 and -1
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have been detected in humans (Kleemann-Ficher, 2001) but not in mice (Klatt et al.
2000). Mouse Matn-3 is highly homologous to human and chicken (Klatt et al. 2000). In
mouse, earliest expression of Matn-3 could be detected at E12.5 in cartilage anlagen of
developing bones and in newborn mice; it is expressed in developing occipital bones and
bones of nasal cavity. At E14.5 it was detected in the cartilage primodium of the vertebral
bodies, the ribs, sternum, trachea, as well as the long bones (Klatt et al. 2000; Klatt et al.
2002). In six week-old mice, its expression was restricted to the growth plates of the long
bones, sternum and vertebrae (Klatt et al. 2002). In addition to cartilaginous tissues,
Matn-3 is expressed in the osteoid around the osteoblasts attached to bone trabecula in
the subchondral bone and around the osteocytes inside the cancellous bone (Klatt et al.
2000). In limbs, Matn-3 is highly expressed in proliferating chondrocytes, weakly in
resting cartilage, while no expression was detected in the hypertrophic zone (Klatt et al.
2000). Matn-3 is also expressed in and secreted by osteoblasts (Klatt et al. 2000). All four
members of the matrilins are expressed during mouse development (Klatt et al. 2000),
suggesting that they may play an important role in endochondral bone formation.
Although MATN-1 and -3 co-localize due to their ability to form heterodimers, they differ
in their spatial and temporal expression. Only MATN-3 but not MATN-1 is detected in a
region adjacent to the resting cartilage of the developing joint. Furthermore, Matn-3
expression gradually ceases after birth, while Matn-1 is continuously expressed in
cartilage throughout life (Klatt et al. 2002).
Mutation in vWF-A domain of human MATN-3 gene leads to autosomal dominant
skeletal disorder, such as multiple osteochondroplasia (MED), a form of
osteochondrodysplasia that is characterized by short stature, delayed and irregular
ossification of the epiphyses and early onset of osteoarthritis (Chapman et al. 2001). In
addition, MATN-3 was reported to be highly upregulated in human osteoarthritic cartilage
and a missense mutation in MATN-3 was implicated in hand arthritis in a group of
patients in Iceland (Stefansson et al. 2003). Another study by Ko et al (Ko et al. 2004)
showed that absence of Matn-3 had no obvious effects on mouse skeletal development.
However, they suggest that other members of the Matrilin family may compensate for
Matn-3.
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Tenascins: Tenascins are a family of large oligomeric glycoproteins primarily
found in the ECM of vertebrates. To date, five members of the family have been
identified in mammals: tenascin-X (TNX or TNXB), tenascin-C (TNC or cytotactin),
tenascin-R (TNR), tenascin-W (TNW), and tenascin-N (TNN) (Hsia et al. 2005). All
members of the tenascin family have common motifs and are characterized by N-terminal
globular domain and heptad repeats, which facilitate multimerization, followed by one or
more EGF-like repeats, several fibronectin (FN) type III domain repeats, and a Cterminal fibrinogen-like globular domain (Weber et al. 1999). All vertebrates express
more than one tenascin gene and each member has a distinctive expression pattern, and
their expression is regulated during development and throughout the organism’s life span.
Different connective cells secrete different types of tenascins and they contribute to ECM
structure and influence the function and behavior of the cells in contact with them.
Several studies suggest that tenascins play an important role in regulating cellextracellular matrix interaction, thus promoting cell rounding, migration and
differentiation (Chiquet et al. 1994; Matsumoto et al. 1994). This protein family plays an
important role during embryogenesis as well as during pathological states in adults such
as inflammatory disease, tissue injury, tumorigenesis and wound healing (Tucker et al.
2006).
Tenascin-x (Tnx, Tnxb): TNX is the largest known member of the
tenascin family. TNX gene lies in the major histocompatibility complex (MHC) class
region in both human and mouse and it overlaps the gene encoding 21-hydroxylase and a
gene encoding an untranslated adrenal specific RNA on human chromosome 6 (Bristow
et al. 1993). Although TNX is capable of forming trimers, it differs from other family
members in that it is unable to form hexamers because it lacks the N-terminal cysteine
residues that are required for hexamer formation. It has 18.5 EGF-like repeats and 29
(mouse) or 32 (human) FN type III repeats domains. Furthermore, unlike TNC and TNR,
TNX is not heavily glycosylated and does not contain the RGD sequence, and hence
cannot bind to RGD-dependent receptors (Bristow et al. 1993).
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TNX is known to interact with several ECM proteins. C-terminal domains of TNX
bind to major fibrillar collagens like COL-1, -3, -5, -6 and topoelastin (Minamitani et al.
2004; Egging et al. 2007). Bovine and murine Tnx bind heparin (Matsumoto et al. 1994;
Lethias et al. 2001) and since this heparin-binding site is also involved in the binding of
TNX to decorin, a proteoglycan, it is suggested that TNX interacts with collagen fibrils
through decorin and this association contributes greatly to the integrity of ECM
(Elefteriou et al. 2001). TNX is also involved in cell-matrix and cell-cell adhesion. TNXnull fibroblasts exhibit adhesive defect in ECM (Minamitani et al. 2004). TNX is also
known to modulate fibrillogenesis and expression of COL-6. TNX increases the rate of
collagen deposition while COL -6 accelerates the rate of collagen formation (Minamitani
et al. 2004).
TNX is widely expressed during human fetal development, with high levels of
expression in testis, skeletal, cardiac, and smooth muscle. In adults expression is limited
to musculoskeletal, dermis, and cardiac tissues (Hsia et al. 2005). TNX expression is also
detected in adult peripheral nerves. Investigations into the mechanisms of Tnx activity in
the cardiac and skeletal muscle suggest that the protein exerts functions during
morphogenesis and cell migration in connective tissues (Burch et al. 1997). Tnx
expression is complementary to Tnc during mouse heart development, (Elefteriou et al.
2001), but its expression is often reciprocal to Tnc in several adult and fetal tissues
(Matsumoto et al. 1994; Geffrotin et al. 1995; Imanaka-Yoshida et al. 2003). In pigs, it is
significantly expressed in two thirds of the 28 tissues examined while Tnc is expressed in
50% of them. Tnx is highly expressed in adult and fetal nerves, dermis, skin, heart,
uterus, placenta, and aorta, lung, mammary gland, stomach, skeletal and adrenal gland of
fetuses. In contrast, Tnc is highly expressed in fetal brain and adult spinal cord, ligament,
tendon, and colon (Geffrotin et al. 1995). TNX is also expressed in human intervertebral
discs throughout the annulus (Gruber et al. 2002).
TNX deficiency in humans is associated with a clinically distinct, autosomal
recessive form of Ehlers-Danlos Syndrome (EDS), which is characterized, by
hyperextensible skin, hypermobile joints, and tissue fragility (Schalkwijk et al. 2001).
Even though haploinsufficiency of TNX is associated with EDS, it is distinguished from
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the classic autosomal dominant EDS by its mode of inheritance, lack of atrophic scars
and an etiology due to a mutation in a gene that does not encode a fibrillar collagen or
collagen-modifying enzyme (Zweers et al. 2005). Tnx null mice were viable and normal
at birth. The skin of these mutant mice was histologically normal, but was noticeably
hyperextensible. Collagen content was significantly reduced although Tnx skin fibroblasts
synthesized near normal amount of Col-1. This discrepancy was attributed to a significant
reduction in collagen deposition thus confirming the hypothesis that TNX deficiency
causes EDS through regulation of collagen fibril deposition into the matrix and not by
interfering with collagen synthesis or processing as observed in other forms of EDS.
(Mao et al. 2002; Bristow et al. 2005).
The mechanism by which TNX regulates fibrillogenesis is not clear but a recent
report suggests that TNX can affect the rate of collagen fibril formation either by directly
binding to collagen or through regulating the synthesis of COL-6, which is known to
affect fibril formation (Minamitani et al. 2004). Moreover, Letias et al. (Lethias et al.
2001) reported that TNX is capable of binding decorin, which is known to bind collagen
and regulate fibrillogenesis (Elefteriou et al. 2001). TNX also seems to regulate
elastogenesis and matrix remodeling. Patients deficient in TNX have abnormal elastic
fibers characterized by fragmented clumped elastic fibers (Zweers et al. 2005).
Furthermore, fibrilin-2 and stromelysin, a protease and regulator of α-1 proteinase
inhibitor that binds and inhibits elastase were significantly upregulated in Tnx null mice
fibroblasts (Bristow et al. 2005). These studies indicate that TNX plays an important role
in maturation and/or maintenance of higher order collagen structures in the ECM and the
elastic network.
Tenascin c (tnc): TNC (haxabrachion or cytotactin) is a hexameric,
multidomain ECM glycoprotein with a spatially and temporally restricted tissue
distribution. Each subunit of hexameric protein consists of N-terminal tenascin assembly
domain (TA), followed by 14.5 EGF-like repeats, and 8 FN type III repeats (Gulcher et
al. 1991). TNC is known to interact with cell surface proteoglycans, fibronectin, and
various collagens (Hoffman et al. 1988; Chiquet-Ehrismann 1991; Salmivirta et al. 1991).
In the developing embryo, TNC is expressed in the skeletal and nervous system (Tucker
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et al. 1994; Hsia et al. 2005), particularly in myotendenous joints and at insertions of
ligaments and tendons (Thesleff et al. 1988; Chiquet et al. 1994). It is selectively
expressed in mesenchymal condensation sites prior to intramembranous ossification and
chondrogenesis (Mackie et al. 1987). During endochondral ossification it is expressed in
periosteal cells and in osteoblasts that are invading the primary center of ossification.
Transcript levels diminish during chondrocyte differentiation and expression is
undetectable in the matrix surrounding the hypertrophic chondrocytes (Mackie et al.
1987; Mackie et al. 1992). In adult cartilage, it is not expressed or expression becomes
restricted (Pacifici et al. 1993). Although TNC is secreted by osteoblasts, it remains on
the bone surfaces and is rarely incorporated into mineralized matrix (Mackie et al. 1987).
TNC is detectable in small amounts in normal adult tissues such as smooth muscle cells,
endothelial cells, myotendinous tissue, spinal cord, kidney and lung (Soini et al. 1993;
Roth-Kleiner et al. 2004). However, its expression is upregulated sharply in the tissues
undergoing remodeling process as in wound repair, and neovasularization or in
pathological states like tumorigenesis and inflammation (Natali et al. 1991).
Exogenous TNC is known to stimulate chondrogenesis in limb-bud mesenchymal
cells (Mackie et al. 1987). TNC has multiple functions during embryonic development
and postnatal growth, and some of its roles include participation in regulation of cell
proliferation, migration, differentiation, survival, cell adhesion and epithelial
mesenchymal interface formation during organogenesis, tissue repair, and somatic
growth regulation (Saga et al. 1991; Roth-Kleiner et al. 2004). Additionally, TNC
participates in chondrogenesis and cartilage development (Pacifici et al. 1993). Pacifici et
al. (Pacifici et al. 1993) showed that TNC is involved in the genesis and function of
articular chondrocytes. TNC not only regulates chondrocyte development at the epiphysis
of long bone models, but it also assists in maintaining chondrocyte function throughout
postnatal life. The latter involves inhibiting the endochondral ossification process that is
undertaken by the chondrocytes at the metaphysis and diaphysis of skeletal models
(Pacifici 1995). Tnc knockout mice are viable, fertile and phenotypically normal, thus
questioning the critical role of Tnc in embryonic as well as postnatal development (Saga
et al. 1992). However, several reports suggest that lack of phenotype in knockout mice
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may be due to redundant mechanisms, namely the ability of other tenascin family
members, especially Tnx to compensate for Tnc. Additionally, although Tnc knockout
mice were initially reported to be phenotypically normal, several studies have reported
abnormal tissue restoration after injury to skin, cornea, or after glomerulonephritis
(Nakao et al. 1998; Matsuda et al. 1999) and abnormal behavior due to reduced
production of certain neurotransmitters (Tamaoki et al. 2005).
Proteoglycan 4 (Prg4): PRG4, also known as Lubricin or Megakaryocytestimulating factor (MSF) or superficial zone protein (SZP), is a large multifaceted,
cytoprotective proteoglycan. It is a major component of synovial fluid that acts as a major
lubricant in articular cartilage; protecting the cartilage surface from friction-induced
wear, protein deposition and cell adhesion and also preventing synovial outgrowth. PRG4
is produced and secreted by synovial cells and superficial zone chondrocytes and is
expressed in superficial zone of both adult and fetal articular cartilage, synovial cells,
bone, liver, heart, and lung. (Rhee et al. 2005).
PRG4 is a paralog of vitronectin and contains multiple domains that are likely to
contribute its diverse biological functions (Rhee et al. 2005). It contains somatomedian B
(SMB) and O-linked glycosylated homopenin-like (PEX) and mucin- like domains. In
vitronectin, both SMB and PEX domains have been known to mediate extracellular
matrix attachment, promote cell attachment and proliferation, and regulate the
complement and coagulation system (Deng et al. 2001). The negatively charged sugars in
mucin-like domains enable the PRG4 to act as a lubricant due to strong repulsive
hydration forces (Jay 1992). Additionally, diverse biological functions have been
attributed to other mucin-containing proteins such as proteins of epithelial surfaces,
which control cell growth and regulate cell differentiation (Van Klinken et al. 1995;
Simmons et al. 2001). Furthermore, its increased expression during ectopic ossification in
mouse also suggests that Prg4 may be involved in the regulation of ossification (Ikegawa
et al. 2000). Loss-of-function mutation in PRG4 causes the rare, autosomal recessive
disease Comtodactyly-arthropathy-coxavara-pericarditis syndrome (CACP), which is
characterized by precocious joint failure (Marcelino et al. 1999). Prg4 knockout mice
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exhibit similar defects as CACP patients and have severe joint pathology due to abnormal
protein deposits on cartilage surface, articular cartilage destruction and marked synovial
cell outgrowth (Rhee et al. 2005). Early loss of PRG 4 from cartilage surface in
association with a decrease in its expression in chondrocytes implicates PRG 4 in the
pathogenesis of osteoarthrits (Young et al. 2006).
Thombospondin III (Thbs3, Tsp-3): TSP-3 is a member of a family of modular,
multifunctional glycoproteins that mediate interactions between cells and ECM (Adams
et al. 1993). The thrombospondin family consists of five structurally related genes
designated as TSP-1, -2, -3, -4 and COMP (cartilage oligomeric matrix protein). TSP-3 is
an oligomeric heparin binding protein that resembles TSP-1 and -2 in its C-terminal
domain, which includes seven type III (Ca2+ binding repeats) and carboxy terminal
region. TSP-3 contains a distinct N terminus and four type II EGF like repeats but it lacks
procollagen homology and type I repeats that are found in TSP-1, -2 and -4 (Bornstein
1992). TSPs are known to interact and bind to cell surface molecules like heparin sulfate
proteoglycans, αγβ3 integrins, glycoprotein IV, sulfated glycolipids and to ECM proteins
like COL-1 and COLl-5, fibronectin and laminin (Frazier 1991).
TSP-1, -2 and -3 are expressed in a unique spatio-temporal manner during murine
embryogenesis, especially in the nervous system, gut, cartilage and lung. In general TSP3 is highly expressed in endocrine, muscle and fetal tissue (Qabar et al. 1994). Several
studies show that TSP-3 is expressed in the early articular cartilage while TSP-1 is
expressed in early or immature chondrocytes (Tucker et al. 1997). On day 19, Tsp-3
expression was also high in the sternum and vertebral bodies, especially in perichondrium
and hypertrophic chondrocytes, and it was expressed in moderate levels in the spinal cord
and brain (Qabar et al. 1994). In addition, in postnatal bovine tissues, Tsp-3 is almost
exclusively expressed in chondrocytes (Qabar et al. 1994) and in four week old mice, it is
highly expressed in lungs, bone, tail, skin, skeletal muscle and heart (Vos et al. 1992).
Gruber et al (Gruber et al. 2006) recently reported the presence of TSP in the outer
annulus of both human and sand rat intervertebral discs, indicating a role for TSP in
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maintenance of disc health (maintenance of avascular status) in adult human and sand
rats.
In general, TSP family members have been implicated in a large number of
cellular processes such as embryonic development, tissue differentiation, blood
coagulation, tumor growth and metastasis, angiogenesis, nerve development, wound
healing and inflammation (Frazier 1991; Adams et al. 1993; Bornstein et al. 1994). They
have been known to regulate cell-matrix interaction (may increase or decrease these
interactions), inhibit endothelial cell growth but stimulate neutrite outgrowth and smooth
muscle cells, stimulate chemotaxis and inhibit angiogenesis (reviewed in (Vos et al.
1992). Even though both human and mouse TSP-3’s have been characterized, their
functions remain unclear. However, based on several studies mentioned above, it may
play a role in chondrogenesis, and in the development of lung and central nervous system
during embryogenesis. Since TSP-3 and other members of TSP family are sometimes
expressed in complementary pattern and also due to its structural similarity with other
family members, TSP-3 may have some similar functions or its functions could overlap
with other members of the family. Tsp-3 null mice are viable, fertile and show normal
prenatal skeletal development. However, developing postnatal skeleton showed subtle
and transient abnormalities. Tsp-knockout mice exhibit more mature skeleton and
accelerated the rate of endochondral ossification in the cartilage of femoral head
(Hankenson et al. 2005). These results along with the presence of TSP-3 in cartilage and
bone suggest that TSP-3 plays an important role in the regulation of postnatal bone
modeling, maturation and endochondral ossification.
Chondroadherin (chad): CHAD is a noncollagenous ECM protein and is a
unique member of the small leucine rich repeat (LRR) proteoglycan family. Unlike other
LRR proteins CHAD shows restricted tissue distribution. Under normal conditions its
expression is mainly confined to tendons and cartilage (femoral head and rib cartilage),
bone marrow and is also expressed during chondrogenic differentiation of mesenchymal
stem cells. (Shen et al. 1998; Barry et al. 2001). It is known to bind to COL-2. Both COL2 and Chad bind to chondrocytes partly via α2β integrin but elicit different cellular
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responses. It has been suggested that sharing one of the receptors on chondrocytes and by
interacting with each other, both COL-2 and CHAD may facilitate cell communication
with their surrounding matrix and/or regulate collagen fibril assembly. (Mansson et al.
2001). CHAD may mediate attachment and/or cell signaling by interacting with α2β on
cells. Temporal expression of CHAD during skeletal development suggests that it plays
an important role in the regulation of chondrocyte growth and proliferation (Mansson et
al. 2001). Additionally, CHAD promotes attachment of osteoblasts to solid-state
substrates and binds collagen, suggesting that Chad is important in maintaining
osteoblasts on the collagen matrices of bone (Mizuno et al. 1996).

BONE MORPHOGENETIC PROTEINS (BMP) AND BMP RECEPTORS
(BMPRs): BMPs are members of the Transforming growth factor (TGF-β) superfamily
that regulate cell proliferation, differentiation and apoptosis in many cell types including,
bone and cartilage cells, monocytes, neural cells, and epithelial cells (Sakou 1998). These
proteins were first identified by their ability to promote ectopic cartilage and bone
development. BMPs induce differentiation of mesenchymal cells into osteoblast and
chondrocyte lineage cells in vitro (Ahrens et al. 1993). BMP-2, -4, -7 (osteogenic protein)
mediate bone and cartilage formation in vivo (Wozney et al. 1988), while GDF-5
(cartilage derived morphogenetic protein 1) and GDF-6 induce formation of cartilage and
tendon-like structures in vivo (Hotten et al. 1996; Wolfman et al. 1997). Several studies
show that induction of mesenchymal cell differentiation toward cells of osteogenic
lineage, promotion of osteoblastic maturation and function by BMPS are mediated by
Smad1/5 and OSF-2/RUNX2 (Gori et al. 1999; Lee et al. 2000). OSF-2/ RUNX2 is
upregulated by BMP-2, -4, and -7 via MSX-2 in multipotential, osteoblastic and
chondroprogenitor cell lines (Tsuji et al. 1998; Gori et al. 1999). BMPs stimulated
chondrocyte maturation and the enhancement of the function of chondrocytes is mediated
by SOX9, a gene critical for chondrogenesis (Semba et al. 2000). BMP-2, -4, and –6
induce SOX9 and over-expression of BMP-2 and -4 results in increase in chondrocyte
number and cartilage formation (Duprez et al. 1996). Additionally, interaction between
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BMPs, Smads and OSF-2/RUNX2 is required for chondrogenesis and COL-10
transcription during chondrogenesis (Leboy et al. 2001).
The importance of BMPs in bone development has been demonstrated by mouse
gene knockout studies. Mice deficient in Bmp-2 and -4 are not viable. In conditional
Bmp-2 and -4 knockout mice, chondrogenic condensations fail to form and osteogenesis
was severely impaired (Bandyopadhyay 2006). The Bmp-6 null mice are viable and
fertile and exhibited a delay in the ossification of the sternum (Solloway et al. 1998).
Bmp-7 mice die after birth because of poor kidney development. In addition, these mice
have eye defects and modest defects in skeleton such as fused ribs and skull, hind limb
defects and vertebral defects such as lack of fusion of the neural spines of the atlas,
twelfth thoracic and first sacral vertebrae, and opening on the sides of the neural arches of
the third and fourth thoracic vertebrae and the absence of lumbar vertebrae. Intervertebral
discs have unequal thickness and mutants have small or no ossification centers (Jena et
al. 1997).
BMPs exert their biological effects by binding to heterotrimeric complexes of
type I (BMPR-1A) and type II (BMPR-1B) serine/threonine kinase receptors. Upon BMP
binding, constitutively active BMPR-1B transphosphorylates BMPR-1A. Activated
BMPR-1A then phosphorylates/activates intracellular Smads, which then translocate to
nucleus and regulate the transcription of target genes (ten Dijke et al. 1994). Both
receptors can bind to BMP-2, -4, -7 and GDF-5. In the chick, Bmpr-1a is expressed in
joint interzones, perichondrium, periarticular cartilage, and hypertrophic chondrocytes
while Bmpr-1b is expressed primarily in condensing precartilaginous mesenchymal cells,
perichondrium and periarticular cartilage (Dewulf et al. 1995; Yoon et al. 2005). In mice,
both of these receptors are expressed in pre-cartilaginous mesenchymal cells (Yoon et al.
2005). Several reports show that BMP signaling via Bmpr-1a and -1b are essential for
multiple aspects of early chondrogenesis and both BMP receptors have some overlapping
functions (Yoon et al. 2005). The constitutively active forms of Bmpr-1a or Bmpr-1b
promote chondrogenesis. A null mutation in the Bmpr-1b gene produce viable mice with
defects confined to phalangeal elements while Bmpr-1a deficient mice die during
gastrulation (Mishina et al. 1995; Baur et al. 2000). Bmpr-1a conditional knockout mice
35

(Bmpr-1acko) have similar and few skeletal defects like Bmpr-1b null mice, and both
Bmpr-1acko and Bmpr-1b-/- double mutants develop severe and generalized chondroplasia
(Yoon et al. 2005). Additionally, over-expression of Bmpr-1a rescued the differentiation
defect of pre-chondrogenic cells in Bmpr-1b null mice (Kobayashi et al. 2005). These
reports show that Bmpr-1a and -1b have overlapping functions in chondrogenesis. In
Bmpr-1a cko mice, ossification of long bones is delayed, bone sizes are reduced and
ribcage is smaller and flattened, leading to respiratory distress and subsequent death. In
both Bmpr-1a and -1b double conditional null mice, majority of skeletal elements that
form through endochondral ossification are absent or malformed presumably due to
impaired differentiation of prechondrocytes into chondrocytes. Moreover, the expression
of cartilage specific ECM proteins (Col-2, Col-10 and aggrecan) is severely reduced in
mutants. In contrast, development of clavicles and craniofacial bones, which form
through intramembranous ossification, is not affected in these mutant mice. (Yoon et al.
2005).

NELL1: A NOVEL CELL DIFFERENTIATION SIGNALING PROTEIN IN
BONE AND CARTILAGE DEVELOPMENT
Several specific growth factors and transcription factors are known to regulate
both osteoblast and chondrocyte proliferation and differentiation. As discussed in the
previous section, many growth factors like FGF-3, TGF-β, BMPs and transcription factor
like OSF-2/RUNX2 are already known to regulate osteoblast/chondrocyte differentiation.
In the past decade, increasing evidence from several studies, including the work
presented in this dissertation, have identified a novel signaling protein, designated as
Nell1/NELL1 that controls cell differentiation in bone, cartilage and muscle (Kuroda et al.
1999; Zhang et al. 2002; Desai et al. 2006).
GENE AND PROTEIN STRUCTURE: In 1995, Matsuhashi et al. (Matsuhashi et al.
1995) cloned the gene encoding a novel protein from a chicken embryonic cDNA and
designated this protein as nel (neural epidermal growth factor-like) because it was
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strongly expressed in neural tissues and contained six EGF-like domains. In the following
year, Watanabe et al. (Watanabe et al. 1996) cloned two novel genes from a human fetal
brain cDNA library that were homologues of nel like type 1 (NELL1) and nel like type 2
(NELL2). Kuroda et al. (Kuroda et al. 1999) then used a yeast two-hybrid system to clone
closely related genes coding for Nell1 proteins from a rat brain cDNA library, which
were mapped to human chromosomal bands 11p15.1-p15.2 and 112q13.11-q13.12
respectively. Human NELL1 is highly homologous to rat (87%) and mouse (87%) at the
nucleotide level. NELL1 is a large gene, ~ 1mb (907311 bp) in length, with a transcript of
3245 bp, which encodes an 810 amino acid protein. Mouse Nell1 is 889138 bp long with
a transcript of 2812 bp, which encodes an 810 amino acid protein. Both human and
mouse NELL1/Nell1 have 20 exons while rat has 24 exons. [http://www.ensembl.org,
(Desai et al. 2006)].
The NELL1 gene encodes a 90 Kda polypeptide that is glycosylated and then
processed into a 130 Kda cytoplasmic protein and is secreted as a 400 Kda trimeric form
(Kuroda et al. 1999). NELL1 is a complex multidomain protein. Human NELL1 has a
thrombospondin (TSP)-like domain, Laminin G (LAM G)-like domain, five van
Willbrand factor C (vWC)-like domains and six epidermal growth factor (EGF)-like
domains, while mouse Nell1 has one TSP like domain overlapping the LAM G domain,
one EGF like domain and two vWC like domains (Desai et al. 2006). It is known to bind
to specific forms of PKC (PKC-β1, -δ, -τ) through EGF-like domains and heparin
through its TSP-1 like domain and its vWC domains are involved in oligomerization of
the protein (Kuroda, 1999). Human NELL1 protein shares high homology with mouse
(93%) and rat (92%) Nell1 proteins (Kuroda et al. 1999; Desai et al. 2006).
EXPRESSION PROFILE IN HUMANS AND MOUSE: In mouse, Nell1 expression
was detected as early as embryonic days 11-14 (Ting et al. 1999) and is preferentially
expressed in the craniofacial region (calvarial bones and mandible), during both
embryogenesis and after birth (Zhang et al. 2002). In rat, Nell1 is expressed in neuronal
cell (Kuroda et al. 1999) and calvarial osteoprogenitor cells, but it was largely absent in
rat long bones (Ting et al. 1999). It is expressed in human fetal brain but not in other fetal
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organs like kidney, liver and lung (Ting et al. 1999). In humans, NELL1 is specifically
expressed in osteoblasts and mesenchymal cells around the newly formed bones along the
parasutural bone margins and within the abnormally fusing and recently fused sutures.
Additionally, it was markedly upregulated in prematurely fusing and fused coronal
sutures. Conversely, it was absent or down regulated in patent normal sutures (Zhang et
al. 2002). NELL1 is also expressed in several embryonal neuroepithelial tumors
(neuroblastoma, neurocytoma, and meduloblastoma) (Maeda et al. 2001), leukemic cell
lines (Luce et al. 1999), and Burkitt’s lymphoma Raji cells (Kuroda et al. 1999).
GENE REGULATION AND ASSOCIATED PATHWAY(S): NELL1 is regulated by
several growth factors and transcription factors. Osteoinductive growth factors like FGF2 and TGF-β1 stimulate NELL1 expression while BMP-2 had no direct effect on it
(Aghaloo et al. 2006). Nell1 seems to operate downstream of these growth factors
because there is no change in the expression of Tgf-β1, -β2, -β3 or Tgf-β/Bmp receptor
and Fgfr/Fgfr2 in Nell1 infected MC3T3 cells (mouse calvarial osteoblast cell line)
(Zhang et al. 2002). Furthermore, NELL1 expression is also modulated by transcription
factors such as MSX-2 and OSF-2/RUNX2. NELL1 promoter contains multiple conserved
MSX-2 and OSF-2/RUNX2 binding sites. Fetal rat calvarial cells (FRCCs) transfected
with Osf-2/Runx2 upregulated NELL1 expression, while Nell1 did not upregulate Osf2/Runx2 expression (Lu et al. 2007; Truong et al. 2007). This shows that Nell1 functions
downstream of Osf-2/Runx2 and is directly regulated by it. In contrast, Msx-2 transfection
and Osf-2/Runx2/Msx-2 co-transfection of FRCCs downregulated Nell1 expression
(Zhang, 2002). MSX-2 functions upstream of OSF-2/RUNX2 and suppresses its
transcription (Shirakabe et al. 2001; Yoshizawa et al. 2004).
NELLl is known to regulate the expression of several genes, which are involved in
bone development. It is known to upregulate osteoblastic differentiation marker genes
like OPN, OCN, BSP and chondrocyte differentiation marker COL-10 (Zhang et al. 2002;
Cowan et al. 2006).
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FUNCTIONS: NELL1 is a newly characterized gene and its functions in the mammalian
system are just beginning to be elucidated. After the identification of the human gene
sequence, the NELL1 protein was predicted to facilitate cell growth and differentiation
based on the presence of EGF-like domains. The capability to bind heparin through TSPlike domains, further suggested that it signals osteogenic differentiation. (Kuroda et al.
1999). Several recent studies using in vitro systems and in vivo mutant mouse models
(including the work described herein) have revealed significant insights into the nature
and mechanisms of NELL1/Nell1 function.
Overexpression of human NELL1 in the cranial sutures is associated with
unilateral coronal craniosynostosis (UCS), the premature closure of cranial sutures in
newborns (Ting et al. 1999). Zhang et al (Zhang et al. 2002) further characterized the role
of Nell1 in suture fusion by creating an overexpressing transgenic mouse model. Since
the complete gene sequence of the mouse Nell1 was not available unlike the rat and
human genes at the time of this study, the rat gene was used to create transgenic mice
overexpressing Nell1 protein. Despite generalized, non tissue-specific overexpression of
Nell1, the skeletal defects in these mice were restricted to the calvarial bones. The
transgenic mice exhibited CS and no apparent defects in other organs. As in human CS,
transgenic mice exhibited prematurely closing/closed sutures and the osteogenic fronts of
these abnormally closing/closed sutures exhibited calvarial outgrowth and overlap along
with reduced proliferation and increased osteoblast differentiation. In vitro studies were
consistent with the transgenic mouse data since Nell1 overexpression in FRCCs and
MC3T3 accelerated osteoblast differentiation and mineralization along with upregulation
of late osteoblast differentiation markers like Opn, Ocn and Bmp-7. Conversely,
downregulation of Nell1 in vitro, reduced Ocn and Opn expression and delayed
osteoblast differentiation (Zhang et al. 2002).
Several reports show that Nell1 also has a profound effect on osteoblast and
chondrocyte apoptosis. A study by Zhang et al (Zhang et al. 2003) indicated that Nell1
modulates calvarial osteoblast differentiation and apoptosis pathways during
intramembranous ossification in the developing skull. The Nell1 overexpression
transgenic mouse model exhibited various degrees of CS and showed increased apoptosis
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in calvarial osteoblast. Also, overexpression of Nell1 in FRCCs and MC3T3 cells induced
apoptosis. These studies suggest that dysregulation of proliferation, differentiation and
apoptosis along with imbalance between osteogenic inducers and inhibitors at osteogenic
fronts in calvarial bones leads to premature suture closure. They further suggested that
the overexpression of NELL1 disrupts the delicate balance between proliferation,
differentiation and apoptotic pathways and this in turn leads to craniofacial anomalies
such as CS.
A recent study by Zhang et al (Zhang et al. 2006) shows that overexpression of
Nell1 induces acrania-like cranioskeletal deformities. Acrania is a craniofacial
developmental deformity characterized by partial or complete absence of flat bones of
skull with complete, but abnormal development of the brain. Overexpression of Nell1
induced acrania at E15.5 day in mouse embryos, through massive Fas-mediated apoptosis
in osteoblast and neural cells. In the previous Nell1 transgenic model, apoptosis was
induced in differentiated osteoblast but not in undifferentiated mesenchymal cells. In this
new mouse model Nell1 was discovered to regulate cranial neural crest cell
migration/differentiation (Zhang et al. 2006) and to induce apoptosis in these cells with
subsequent acrania. This study further suggests that moderate upregulation of Nell1 leads
to increased osteoblast differentiation and CS, while exaggerated overexpression of Nell1
like in Nell1 transgenic mice model induces massive apoptosis in osteoblast and cranial
neural crest cells and subsequently neural tube defect like acrania (Zhang et al. 2002;
Zhang et al. 2006).
The earlier reports have demonstrated unequivocally that Nell1 plays a critical
role during intramembranous bone formation. The focus of these studies was on the effect
of Nell1 on calvarial osteoblast biology and craniofacial development. However, several
recent studies show that Nell1 regulates intramembranous as well as endochondral bone
development. The work described here represents the first report on the involvement of
Nell1 in chondrogenesis and endochondral ossification (Desai et al. 2006). Recently,
Cowan et al (Cowan et al. 2006) reported that Nell1 accelerates chondrocyte hypertrophy
and endochondral bone formation within the distracted maxillary suture. When
overexpressed, it also induced premature hypertrophy and increased apoptosis of
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chondrocytes, which in turn leads to distortion of chondrocranium and subsequent
acrania-like cranial deformity during mouse development (Zhang et al. 2006).
Furthermore, several recent reports show that NELL1 frequently undergoes loss of
heterozygosity (LOH) in human cancers (Dolan et al. 1998; Jin et al. 2007). LOH and
promoter hypermethylation are few of the mechanisms that lead to gene inactivation
(Knudson 2001). NELL1 promoter is hypermethylated in esophageal adenocarcinoma and
squamous cell carcinoma (Jin et al. 2007), colon cancer (Mori et al. 2006), and lung
carcinoma (Shiraishi et al. 2002). The promoter hypermethylation has been shown to be
involved in silencing of tumor suppressor genes (Herman et al. 2003). All these studies
suggest that NELL1may function as a tumor suppressor gene in certain human cancers.

PROTEIN KINASE C SIGNALING PATWHAYS AND ITS RELATIONSHIP TO
NELL1: Several previously published reports show that PKC and NELL1 are involved in
the signal transduction pathways that are utilized in osteogenesis and chondrogenesis,
Additionally, NELL1 is known to bind and become phosphorylated by specific isoforms
of PKC (Kuroda et al. 1999; Hay et al. 2001; Rosado et al. 2002; Marie 2003).
Protein kinase C (PKC): PKC comprises a family of serine/threonine kinases that
control a vast variety of cellular functions in various cell types. The PKC family consists
of at least twelve isoforms with different tissue expressions, subcellular localization, and
substrate specificity. These PKC isoforms are involved in signal transduction pathways
that regulate cell proliferation, differentiation, development and apoptosis (Nishizuka
1988). Based on their structure and cofactor requirements, PKC family members are
classified into the following categories: a) classical PKCs (PKC-α, PKC-βII and PKC-γ)
which bind phorbol esters and are Ca2+ dependent, b) novel PKCs (PKC-δ, PKC-ε, PKCη and PKC-θ) that bind phorbol esters but are not Ca2+ dependent, and c) atypical PKCs
(PKC-ι, PKC-ζ, PKC-λ and PKC-μ) which do not bind to either phorbol or Ca2+. (Hug et
al. 1993). Different isoenzymes may have unique or sometimes similar or even opposite
effects on cell growth (Svensson et al. 2000). Most cell types contain more than one
subspecies of PKC.
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The PKC isoenzymes are expressed in a tissue-specific manner (Table. 2.1), and
the amount and number of PKC isoenzymes varies within a given tissue depending on its
developmental stage. PKC-α, -β, -ε and -δ are expressed in osteoblasts (Yang et al.
2002)). Differential expression of PKC isoenzymes was detected during the development
of human fetal vertebral column. PKC-α and -βI were highly expressed and PKC-δ, -βII
and -ζ in moderate amounts in chondrocytes of vertebral bodies, whereas PKC-α, -ζ and
-θ were expressed more in intervertebral space (Bareggi et al. 1995). PKC was expressed
highly in mature cells that are close to ossification centers as well as near vertebral discs
and especially PKC-β and -ε were highly expressed in proliferating chondrocytes and
hypertrophic chondrocytes. The presence and differential expression of PKC isoforms
was detected during the 8th week of developmental age in human fetal vertebral column
when most of the chondrogenic and osteogenic events occur (Bareggi et al. 1995).
PKC is regulated by several growth factors including FGFs, BMPs and TGFs and
parathyroid hormone (Opperman et al. 2000; Marie 2003). These growth factors along
with the transcription factor OSF-2/RUNX2 and NELL1 play a major role in bone and
cartilage development. Members of the FGF family are known to play important roles in
skeletal development and postnatal development and activating mutations of human
FGFR-1, -2, and -3 genes cause craniosynostosis and other skeletal defects (Wilkie
1997). FGFs controls bone formation by regulating the expression of various genes
involved in osteoprogenitor cell proliferation, osteoblast differentiation and apoptosis via
PKC and MAP kinases (ERK and p38 MAP kinases) which in turn regulate transcription
factor like OSF-2/RunX2 and regulate the expression of target genes like COL-1, IL-6,
OCN, OPN, VEGF, alkaline phosphatase and NELL1 (Marie 2003; Aghaloo et al. 2006).
BMPs play a critical role in bone and cartilage development and postnatal bone
formation. They are known to regulate the genes involved in the differentiation of
osteoprogenitor cells, endochondral ossification, chondrogenesis and apoptosis (Hay et
al. 2001; Marie et al. 2002). BMPs are known to mediate their action through PKC and
OSF-2/RUNX2 development pathways (Hay et al. 2001; Lee et al. 2002). TGF-β is a
potent regulator of osteo-chondroprogenitor cell migration and proliferation and
differentiation of osteoblasts and chondrocytes (Mehrara et al. 2002; Rosado et al. 2002).
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Table. 2.1: Tissue Specific Expression of Protein Kinase C (PKC) Isoforms.
PKC Isoforms
PKC-α, -βI/II, -δ, -ε and -ζ
PKC-θ
PKC-η
PKC-ε
PKC-α, -β, -ε and -δ
KC-α, -βI, -δ, -βII and -ζ
PKC-α, -ζ and -θ

Expression
brain, lung, spleen, thymus, skin and liver
(Hug, 1993)
skeletal muscle (+ +), lung, spleen, skin, and
brain (+) (Hug, 1993)
skin and lung (+ +), brain and spleen (+)
(Hug, 1993)
hematopoietic cells and skeletal muscles
(Hug, 1993)
osteoblasts
chondrocytes and vertebral bodies
intervertebral space

+ + Indicates predominant/ strong expression, + indicates moderate expression.
TGF-β is known to upregulate PKC and OSF-2/RUNX2 in both osteoblast and
chondrocytes and mediates some of its biological functions through activating MAP
kinases via PKC and thereby regulates OSF-2/RUNX2 and transcription of target genes
(Lee et al. 2002; Mehrara et al. 2002; Rosado et al. 2002).
As mentioned previously, osteogenic protein NELL1 plays an important role in
bone development. Its overexpression is associated with human craniosynostosis and
regulates osteoblast differentiation and apoptosis during craniofacial development (Zhang
et al. 2002; Zhang et al. 2003). Loss of function mutations in Nell1 results in cranial and
vertebral defects in mouse (Desai et al. 2006). NELL1 interacts and is phosphorylated by
specific isoforms of PKC such as PKC-βI, δ, and -ζ (Kuroda et al. 1999).
Based on findings that FGFs, TGF-β, and BMP upregulate PKC and signal
through PKC via OSF-2/RUNX2 and regulate the genes involved in osteogenesis and
chondrogenesis and the association of NELL1 with certain PKC isoforms and its
regulation by OSF-2/RUNX2, it is very clear that PKC plays a major role in both
intramembranous and endochondral ossification.
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BONE AND CARTILAGE DISORDERS ASSOCIATED WITH NELL1MEDIATED PATHWAYS
Osteogenesis and chondrogenesis are complex processes involving a series of
several coordinated cellular events. Normal bone formation involves a delicate balance
between proliferation, differentiation and apoptosis in osteoblasts and chondrocytes.
Disruption of this balance causes many serious human birth defects and diseases like
craniosynostosis, osteochondrodysplasias, epiphyseal dysplasia, arthritis, and
osteoarthritis etc. Additionally, several osteoblast and chondrocyte ECM proteins like
collagens and number of non-collagenous proteins have crucial roles in both osteogenesis
and chondrogenesis. Mutations or aberrant expression of collagen genes underlie human
diseases such as Osteogenesis imperfecta, some types of Ehlers-Danlos syndrome,
Chondrodysplasias, some forms of osteoporosis and osteoarthritis, arterial and
intracranial aneurisms and epidermolysis bullosa (Prockop et al. 1995).
As previously noted, overexpression of Nell1 is associated with both human and
mouse craniosynostois and acrania-like cranial defects (Ting et al. 1999; Zhang et al.
2002; Zhang et al. 2006) while reduced expression leads to both craniofacial as well as
vertebral column defects. The specific ECM proteins (Col-10), transcription factors (Osf2/Runx2), BMP receptor etc. that are downregulated by aberrant expression of Nell1 are
known to play important roles in both intramembranous and endochondral bone
formation and are also associated with certain form of Ehlers -Danlos syndrome (finding
of the current study) (Desai et al. 2006).
CRANIOSYNOSTOSIS (CS): The mammalian cranial vault consists of five bones: the
pair of frontal and parietal, and the unpaired interparietal bones (Fig.2.5). Interactions
between the developing brain, the growing calvarial bones and the sutures (fibrous joints)
are essential for the coordinated growth of brain and skull (Wilkie 1997). Most calvarial
bones are formed by intramembranous ossification in which mesenchymal cells
differentiate into osteoblast that deposit mineralized bone matrix. Growth of the calvarial
bones occurs in two phases:1) outward growth from the centers of ossification, eventually
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Figure. 2.5: Calvarial Bones and Sutures. (Top View of the Skull)
uniting in fibrous sutures; and 2) growth at the sutures in concert with the expanding
calvarium and brain. These cranial sutures serve as the growth centers of the skull and
allow the skull to enlarge by the appositional growth in concert with the brain. The
sutures also allow calvarial bones to expand without fusing. Continued growth of the
skull vault depends on maintenance of a balance between recruitment of the osteogenic
stem cells, proliferation, differentiation and apoptosis and disruption of this balance leads
to premature or delayed fusion of the sutures and formation of abnormal calvarial bones.
(Cohen 1993; Jiang et al. 2002).
Craniofacial abnormalities are very common birth defects in humans caused by
genetic mutations, exposure to environmental agents and physical stresses (De Pollack et
al. 1996). Craniosynostosis is a heterogeneous disorder characterized by the premature
fusion of one or multiple cranial sutures in newborns. CS affects 1 in 3000 infants and is
one of the most common human congenital craniofacial deformities (Cohen 1993; Wilkie
1997). In CS, constrained brain growth due to cessation of skull growth leads to a severe
cranial dysmorphism, often leading to increased intracranial pressure, impaired cerebral
flow, airway obstruction, impaired vision and hearing, and mental retardation requiring
series of major cranial surgeries in infants or young children (Fig.2.6).
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Figure. 2.6: Human Craniosynostosis. An infant with a unilateral coronalsynostosis. Arrow
indicates prematurely fused left coronal suture resulting in a disproportionate growth of the brain into the
right side of the cranium.
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(Wilkie 1997; Carver et al. 2002). Additionally, certain types of CS are associated with
defects in the limb and spine development (Anderson et al. 1996; Anderson et al. 1997)
suggesting craniofacial, rib and spine development utilize common molecular pathways.
Mutations in several genes are known to cause CS. Gain of function mutations in FGFR1, -2, and -3 are linked to several syndromes involving CS, such as Apert Syndrome,
Pfeiffer Syndrome, and Jackson-Weiss Syndrome (Reardon et al. 1994; Lajeunie et al.
1995; Muenke et al. 1997). Furthermore, mutations in transcription factors that regulate
osteoblast proliferation and differentiation have been implicated in CS. Gain-of-function
mutations in MSX-2 results in Boston-type CS while, loss-of-function mutations in Twist
are associated with Saethere-Chotzen CS (Howard et al. 1997; Liu et al. 1999).
EHLERS- DANLOS SYNDROME (EDS): EDS is a heterogeneous group of heritable
connective disorders that affect one in five thousand individuals (Mao et al. 2001). There
are six major subtypes of EDS, each with slightly different symptoms and causes.
Complexity of symptoms and lack of specific genetic tests makes diagnosis of
EDS often difficult. The main characteristics of EDS are skin hyperextensibility, tissue
fragility, and joint hypermobility. Additionally, EDS patients also exhibit easy bruising,
prolonged bleeding, delayed wound healing, mitral valve prolapse, and chronic joint pain
(Beighton et al. 1998).
The six major types of EDS are: 1. Classical type (EDS type I and II). It is an
autosomal dominant disorder caused by mutations in COL-5A1 and COL-5A2. 2.
Hypermobility type (EDS type III). It is an autosomal dominant disorder with unknown
genetic defect. 3. Vascular type (EDS IV). It is an autosomal dominant disorder due to
mutation in COL-3A1. 4. Arthrochalasia type (EDS type VII A and B). This autosomal
dominant disorder is due to mutation in COL-A1 and -A2. 5. Dermatosparaxis (EDS type
VII C). Autosomal dominant EDS VII C is due to mutation in Procollagen N-peptidase.
6. Kyphoscoliosis type (EDS VI). This autosomal recessive disorder is due to mutation in
Lysyl hydroxylase 1 (procollagen posttranscriptional modifying enzyme) gene and is
characterized by neonatal onset of kyphoscoliosis, ocular fragility, and joint laxity,
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muscle hypotonia, skin fragility and hyperextensibility. (Beighton et al. 1998; Yeowell et
al. 2000).
Most types of EDS have been attributed to mutations in collagens and collagenmodifying enzymes. However, identification of clinically distinct, recessive type of EDS
caused by mutation in TNX shows that EDS is not solely a disease of collagens. Unlike
other forms of EDS, which are due to aberrant collagen synthesis or processing, TNX
deficiency causes EDS through regulation of collagen fibril deposition and which in turn
leads to a reduction in the amount of collagen and due to elastic fiber abnormalities.
(Bristow et al. 2005; Zweers et al. 2005).
N-ETHYL- N- NITROSOUREA (ENU) MUTAGENESIS
The Nell16R mutant mouse that was characterized in this work was recovered as
part of a large series of recessive lethal mutations in the l7R6 locus generated from a
large-scale ENU mutagenesis experiments conducted at ORNL (Rinchik et al. 1999;
Rinchik 2000; Rinchik et al. 2002). ENU is the most potent germline mutagen of the
mouse genome. In spermatogonial stem cells, ENU induces mutations at a frequency of
~6-1.5 x10-3 i.e. one mutation /gene/175-655 gametes screened (Justice et al. 1999). It is
an alkylating agent that induces random point mutations by transferring its ethyl groups
to oxygen or nitrogen radicals in nucleic acids causing inaccurate DNA replication.
Subsequent mispairing leads to single base-pair substitution preferentially in AT base
pairs. In mouse, it predominantly modifies A/T base pairs (44% A/T → T/A/
transversions) and also induces A/T → G/C transitions (38%). These changes result in
64% missense mutation, 26% abnormal splicing, and 10% nonsense mutations. (Justice et
al. 1999; Noveroske et al. 2000). Large scale phenotype-driven ENU mutagenesis
experiments can be used to identify dominant as well as recessive traits and is useful for
creating a series of mutant alleles for a single gene to uncover multiple gene functions.
This mutagenesis strategy does not require any prior knowledge of specific gene or its
function (Herron et al. 2002). ENU can be used to generate a large number of mutants
with specific phenotypes of interest and obtain mutants that display a various degree of
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mutation, from complete to partial loss of function, as well as exaggerated function
(Justice et al. 1999).
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CHAPTER 3
MATERIALS AND METHODS
MOUSE BREEDING AND MAINTENANCE
All the animals were bred at the Mammalian Genetic Research Facility at ORNL.
Large-scale N-ethyl- N- nitrosourea (ENU) mouse mutagenesis experiments conducted at
ORNL have yielded several recessive lethal mutant alleles for the l7R6 locus on mouse
chromosome 7 (Chr 7) proximal to p (Pink-eyed dilution) gene. The identification and
fine structure mapping of the l7R6 locus in mouse Chr 7 was conducted by Rinchik et al.
(Rinchik et al. 2002). One of the mutated alleles of l7R6 locus, 102DSJ (Nell16R) was
induced in the p chromosome from non-inbred, closed-colony 21A strain.

GENERATION OF MUTANT HEMIZYGOTES AND HOMOZYGOTES FOR
DSJ LINE: The ENU mutagenesis strategy used by Rinchik et al. (Rinchik et al. 2002)
to generate the DSJ line was conducted by treating non-inbred Go males 21A (a/a; p/p)
mice with four weekly intraperitoneal injections (85mg/kg each) of ENU. Treated males
were mated with wild-type females [F1 (C57BL/10R1 X C3H/R1) or F1 (C57BL/6JRn X
C3H/R1) or C3H/R1]. All the G1 animals from this cross that carry a mutation (m)
induced in parental genome in Chr 7 were recovered by linkage to the pink-eyed dilution
locus (p). The p gene is tightly linked to l7R6 locus/mutation. The p locus is one of the
coat color mutations in mouse chromosome 7. It is one of the loci used as markers for
experimental mutagenesis at ORNL. Animals carrying wild-type allele exhibit intense
pigmentation in both skin and eye while animals with recessive alleles (p/p) exhibit
reduced or no pigmentation (Lyon et al. 1992; Johnson et al. 1995). The px is an
intermediate allele of p. Animals homozygous for px have a darker eye/coat color and
lighter eye/coat color when heterozygous with most null p mutations (Rinchik 2000). The
G1 females were then crossed with a/a; px/ Del (ru2p) 46DfioD males. In G2 progeny ENUinduced recessive mutations closely linked to p and included within the deleted segment
in Del (ru2p) 46DFioD were recovered in the pink-eyed dilute class (m p/ Del (ru2p) 46DfioD.
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In G2 progeny, three different eye pigment phenotypes were generated to correspond with
the genotype at the mutant locus: wild-type (dark pigment, +/px or +/ Del (ru2p) 46DfioD),
Heterozygote (light pigment, m p/+ px), and hemizygote (no pigment, m p/ Del (ru2p)
46DFioD

) (Fig. 3.1A). [(Rinchik 2000) http://bio.lsd.ornl.gov/mgd/index.html].
To generate fetuses hemizygous for 102DSJ, progeny-tested males + px / l7R66R

were mated with + px/ Del (Hps5ru2 p) 46DFiOD females. The 102DSJ lethal mutation was
recognized when G1 female #102 failed to yield any pink-eyed-dilute G2 progeny when
she was crossed to a + px/Del (Hps5ru2 p) G1 male. The deletion mapping was done as
described in Rinchik et al (2002), which also revealed that the 102DSJ lethal allele
mapped to the same deletion interval as the other l7R6 alleles. To confirm the allelism,
88SJ (Hps5ru2 l7R61R p/Hps5ru2 + +) and 102DSJ (+ 102DSJ p/++px) were crossed. It was
confirmed that l7R66R (102DSJ) was a new allele of l7R6 locus, when the cross failed to
produce more than 30 pink-eyed dilute heterozygote progeny, when 25% were expected
(p<0.001) (Desai et al. 2006)
To generate homozygous l7R66R (102DSJ) mutant mice, the heterozygote carriers
(l7R66R p/+ px X l7R66R p/+ px) were crossed, which produced pink-eyed homozygotes
(l7R66R p/ l7R66R p, no eye pigment), dark-eyed wild-type mice (+ px/+ px), and medium
pigmented heterozygote carriers (l7R66R p/+ px or px/ l7R66R) (Fig.3.1 B).

COLLECTION OF MOUSE EMBRYOS
Mouse matings were done for 1 hour early in the morning, and the females were
examined for the presence of vaginal plugs (gestation day 0). The embryos/fetuses were
collected at 10, 12, 14, 16, 18.5/19 days of gestation. The pregnant females were
euthanized by cervical dislocation and embryos were collected by caesarean section. The
embryos were then examined for eye-pigmentation and associated gross morphological
abnormalities (head shape and size, body length, overall pallor, positioning of
appendages, reflexes and breathing). About 2-3 mm tail tips were snipped for genotyping
by microsatellite analysis. The embryos were sorted based on their eye pigmentation:
Non-pigmented (Nell16R homozygote or hemizygote mutants), light pigmented (Nell16R
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A.

Figure. 3.1: Breeding Protocol Used to Generate Hemizygous and Homozygous
l7R66R (102DSJ) Mice. See text for details. (A). The hemizygous pink-eyed dilute test class (heavily
out lined box) G2 progeny carries the mutant l7R66R allele. Darker “pink” G2 progeny (lightly boxed) carry
mutation, from which mutations can be propagated. (B). Homozygous l7R66R (102DSJ) mutant animals
were obtained from mating darker “pink” carriers (heterozygous for mutation) from G2 generation. Pinkeyed (heavily outlined box) G3 progeny are homozygous for mutation and medium pink-eyed (lightly
outlined box) animals are heterozygous for mutation. The “wild-type” animals are wild-type for l7R66R, but
not for eye pigmentation. m is the mutation induced by ENU; p pink-eyed dilution; px another allele
(intermediate allele) of p gene. [Modified from (http://bio.lsd.ornl.gov/mgd/index.html)].
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B.

Figure. 3.1: Breeding Protocol Used to Generate Hemizygous and Homozygous
l7R66R (102DSJ) Mice. Continued.

.
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heterozygote), and dark pigmented (Nell1 wild-type). Mutants were also easily
distinguished by their slightly enlarged heads, curled position, and weak responses to
touching. Embryos or parts of the embryos (head, body, dissected vertebral column etc)
were collected and fixed as necessary: Frozen in liquid nitrogen for RNA and DNA
extraction or fixed in 10% Formalin for histology.
GENOTYPING OF WILD-TYPE AND l7R6R MUTANTS
Mutant fetuses were distinguished from wild-type by molecular genotyping for
size polymorphisms using D7Mit315 microsatellite, which is tightly linked to p gene,
which in turn is tightly linked to l7R6 locus. The snipped tails were digested in digestion
buffer [200 μl of 1X PCR buffer (Invitrogen) and 20 μl of 10mg/ml Proteinase K] for 2
hours or overnight at 60°C. Proteinase K was deactivated by incubating digests at 95°C
for 20 minutes. Digested DNA from tail snips was amplified by PCR using standard
techniques using 3 μl of DNA from tail snips and primers for microsatellite markers,
D7Mit 315 for DSJ lines (D7Mit315 F: TGATAACAAAACAGFCAGTAATGAAGC
and D7Mit315 R: CTGATCCATC TGT ATGATGTTACTTG). PCR products were
resolved on 3.5% metaphor gel with 0.5 X TBE buffer (Tris, boric acid and EDTA).
Nell16R homozygotes were distinguished by a single 146 bp band, wild-type animals by a
single 166 bp band and heterozygotes, which have two bands, 146 bp and 166 bp.

ISOLATION OF TOTAL AND mRNA
Total RNA was extracted from E10 embryos, head and bodies of E12-E19
fetuses, and adult tissues such as liver, spleen, kidney, thymus, heart, lung and muscle
and also from the heads of E15 17R6 fetuses using standard guanidine isothiocyanate
procedure based on and modified protocol from 5’- 3’ Rapid Total RNA Isolation Kit (5’
Prime → 3’ Prime, Inc, Boulder, CO). RNA was isolated from subsequent phenolchloroform extractions using Phase Lock GelsTM (Eppendorf, Hamburg, Germany) and
precipitated with isopropanol followed by centrifugation and re-suspension of the pellets
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in RNase-free water. The total RNA was further purified by using RNAeasy Mini Kit
(Qiagen, Valencia, CA) including DNase I treatment step according to the manufacturer’s
protocol to eliminate the contaminating genomic DNA. RNA quality was assessed by
visualization in denaturing agarose gel electrophoresis and spectrophotometrically by the
260nm/280nm ratio of absorbance. For some experiments, mRNA was isolated from the
total RNA using QIAGEN Oligotex mRNA isolation kit (Qiagen) according to
manufacturer’s protocol. 500 μg to 1mg of total RNA per sample was used to isolate the
mRNA by Oligotex mRNA spin-columns.
The cDNA probe for Nell1 was generated from the mouse brain mRNA by RTPCR using primers designed from the mouse EST sequences matching 5’ and 3’ ends of
human NELL1 (Primers: ctc55: TGCAGCAGAAGCCTCCA; ctc59:
CAAACTAGGGCAAGCTAGAG). The First-Strand cDNA templates were generated
from mRNA extracted from wild-type E18.5 fetal brain using RETROscript (Ambion,
Austin, TX). A 1920 bp cDNA probe was generated by Long Range PCR using
ExpandTM Long Template PCR System kit (Roche Diagnostics, Switzerland) according to
manufacturer’s instructions and using primers ctc55 and ctc59. The PCR products were
gel purified by using QIAquick Gel Extraction Kit (Qiagen). The cDNA probe spans the
last half of the exon 3 (~55 bp) to first 20 bases of exon 19 of the Nell1 transcript.

Nell1 GENE PROFILING BY NORTHERN BLOT AND RT-PCR
One to three μg of mRNA in a volume of 4.5μl was mixed with 15.5μl of RNA
loading buffer [Formamide 720 μl, Foramaldehyde 260 μl, 10X MOPS (3-NMorpholino-propane-sulfonic acid) 160 μl, 80% Glycerol 100 μl and RNase-free water
80 μl]. The 10X MOPS buffer contains 200 mM MOPS, 50 mM NaOAC, 5 mM EDTA,
and was adjusted to pH 7.0. Samples were denatured at 65°C for 10 minutes, chilled on
ice and loaded onto an RNA gel (1% agrose, 1X MOPS, 24.6% Formaldehyde, 1ng/ml
Ethidium bromide), electrophoresed at 80 volts for 4-5 hours and photographed under
UV light. The gel was incubated in NaOH solution (5ml 10 N NaOH/liter of double
distilled water) for 10 minutes. Nylon membrane (Duralon-UVTM, Stratagene, La Jolla,
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CA) and Whatman filter paper that were cut according to the gel size were equilibrated in
20X SSC buffer (3 M NaCl, 0.3 M sodium citrate). The gel was then transferred to the
Nylon membrane overnight according to the Northern Blot set-up in Sambrook et al.
(Sambrook 1989). The nylon membrane was rinsed in 2X SSC, baked at 80°C in vacuum
oven for 2.5 hours and immediately cross-linked at 250 LED in UV cross-linker. The blot
was then prehybridized by incubating in 1X prehybridization buffer (20X SSC, 0.5 M
NaPO4, pH 7.0, 50X Denhardt’s solution, 10% SDS and 10 mg/ml sonicated salmon
sperm DNA) for at least 2-3 hours at 42°C. Denhardt’s solution contains 1% Ficoll (type
400), 1% polyvinylpyrrolidone (PVP-360), and 1% BSA (bovine serum albumin). 20-40
ng of cDNA probe was labeled with [α-32P]-CTP overnight and precipitated [in ethanol,
3M NaOAc pH 5.2, 10mg/ml yeast tRNA and TE buffer (10 mM Tris, 1 mM EDTA)]
and re-suspended in TE buffer, boiled for 5min at 100°C and hybridized to the blot in
hybridization buffer (50% 2X-prehybridization buffer, 50% formaldehyde) overnight at
42°C. The membrane was washed in 2X SSC containing 0.1% SDS for 30 minutes twice,
in 1X SSC containing 0.1% SDS for 30 minutes at room temperature and then in 0.2X
SSC containing 0.1% SDS for 30-45 minutes at 68°C and exposed to X-ray film at −
80°C.
Expression of Nell1 was further confirmed by RT-PCR analysis. About 500ng of
mRNA from wild-type and mutant fetal heads was reverse transcribed using
RETROscript Kit (Ambion). The two fragments of cDNA were amplified by standard
and long range PCR. The smaller fragment (~ 557 bp) at the 5’ end was generated by
standard PCR techniques using primers ctc138: CTGAAGCATTGGTTTCTTGC and
ctc149: TCGACATGGAGTAGGAGGTGAGAGG and the longer fragment (1465 bp)
spanning the middle and 3’ end of the gene was generated by Long Range PCR
(ExpandTM Long Template PCR System kit, Roche Diagnostics) using primers ctc150:
GCAGAGACGAGACTTGGTCAACTGG and ctc59:
CAAACTAGGGCAAGCTAGAG. The PCR products were resolved on 1% agarose gel
and stained with ethidium bromide and visualized under UV light. The 5’end of the Nell1
amplicon (~557 bp) covers the exons 1 to most of the exon 8 while the amplicon
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spanning the mid and 3’ end of the Nell1 transcript covers the exons 13 to the first ~ 42
bp of exon 19.

GENERATION AND SEQUENCING OF Nell1 cDNA
To generate a full-length mouse Nell1 cDNA sequence, direct sequencing was
performed with the PCR products amplified from cDNA template. Total RNA was
extracted from BJR E18.5 fetuses and then mRNA was isolated from the total RNA. The
cDNA was obtained by generating short 300-400 bp overlapping PCR fragments. To
synthesize the Nell1 cDNA, 500ng of mRNA was reverse transcribed using the
RETROscript kit (Ambion). Eleven overlapping segments covering the entire coding
region plus 5’ and 3’ untranslated regions were generated using the eleven sets of primers
(listed in Table. 3.1) by standard PCR techniques. Primers to produce overlapping
amplicons were designed (based on mouse EST sequences matching human NELL1
cDNA) using Primer3 database (Rozen et al. 2000). The PCR products were
electrophoresed on 1% agarose gel to confirm amplicon size and checked for non-specific
products. The PCR products were purified using QIAquick PCR purification kit (Qiagen)
and the purified amplicons were sequenced (using the primers that generated the
products) bi-directionally using Big Dye version 3.1 dye terminator kit (ABI, Foster City,
CA) and analyzer on an ABI 3100 Genetic Analyzer. The sequenced overlapping cDNA
segments were edited to remove overlaps and assembled into one contiguous segment of
2862 bp. This 2862 bp mouse Nell1 cDNA covers the entire coding region (20 exons)
plus the 58 bp of 5’end and 250 bp of untranslated regions.
To determine the identity and homology of the new mouse sequence to other
mammalian species BLAST analysis was conducted against human, rat and existing
partial sequences from the mouse Celera database [(Altschul et al. 1990);
(http://www.ncbi.nlm.nih.gov/BLAST)]. The coding region for the full-length Nell1
cDNA as well as translated protein sequences was obtained by using NCBI’s ORF finder
http://www.ncbi.nlm.nih.gov/gorf/gorf.html. Additionally, Nell1 protein domains were
predicted using NCBI’s Conserved Domain database
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Table. 3.1: Primers Used to Synthesize and Sequence Mouse Nell1 cDNA.

Primer
Pairs

Sequence of Forward Primers

Sequence of Reverse Primers

ctc138/Jaya1R

CTGAAGCATTGGTTTCTTGC

TGGATGGTTTCTGCTGCA

Jaya 2F/2R

GATGTACAGAGAGAGATCCA

TGCTTCCTGGAGGAAGGTG

Jaya 3F/3R

GGCAGACGGACAATGGCACA

AGTTGACCAAGTCTCGTCTC

Jaya 4F/4R

CCAACATGCAGTGACTTCCT

AGACTCCACCTCGACATTCC

Jaya 5F/5R

CACTTCCTGTGCACATTTCC

GGTGTTGGCATGACAATAGTG

Jaya 6F/6R

ACCTGTGAGTGCAAGAATGG

CAGACACACTTGTTAGGAGC

Jaya 7F/7R

CATCTGTACCAACACAGTCC

GATGCAGGCAGAGTCATTCC

Jaya 8F/8R

ACCACTGTGAGTGCAGAAGC

CTAAACATTGGCTGGTGACC

Jaya 9F/9R

CAGTCTGTTCCTGCAAG

CAGCCTCGAAACACCAAAGC

Jaya 10F/10R

GCTGTGAATACACAGCCATG

GCAATCCAAACGCCTTCCTC

Jaya 11F/ctc174

CTCGTCACGTGAGAAAATGG

GGTGCCAAGTCTCTATTATGTCAG

Frag
ment
Size
356 bp
355 bp
375 bp
400 bp
394 bp
367 bp
370 bp
369 bp
368 bp
370 bp
326 bp

(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). The 2862 bp full-length mouse
Nell1 cDNA sequence with open reading frame of 2433 bp, which encodes 810 amino
acid protein, was submitted to the NCBI’s Gene Bank as accession number (AY622226).
IDENTIFICATION OF MUTATION IN Nell16R
For identifying the Nell16R mutation, direct sequencing was performed with the
PCR products amplified from the genomic DNA templates. DNA was extracted from
Nell16R hemizygous mutant mice and control strains (BJR and 21A). Briefly, tails of
mutant and wild type E18.5 fetuses were snipped and digested in a buffer containing 1M
Tris pH 7.6, 5M NaCl, 0.5M EDTA pH 8.0, 10% SDS and 10mg/ml Proteinase K in SST
tubes (serum separation tubes, Becton Dickinson) overnight at 45°C. DNA was extracted
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by phenol and precipitated with 95% ethanol. Precipitated DNA was collected by a glass
loop and solubilized in TE pH 7.6 buffer. Twenty primer sets were designed to amplify
each exon of Nell1 from flanking intron sequences and two additional primer sets to
amplify conserved upstream elements (listed in Table.3.2). Each amplicon was amplified
from the genomic DNA by standard PCR techniques. The corresponding wild-type and
mutant PCR products were mixed in equal volumes in 96-well plates, heteroduplexed and
scanned for point mutations using Temperature Gradient Capillary Electrophoresis (Li et
al. 2002). Three overlapping temperature gradients were used: 50-60°C, 55-62°C and 6068°C. The heteroduplex formed by the mismatch of the ENU-induced point mutation and
the wild-type segment was detected in exon 14. The 421 bp amplicon containing the
mutation in the l7R66R allele was PCR-amplified using the primer pairs designed from the
intron sequences flanking the 131 bp exon 14 of Nell1: Nell E14 (F):
ATAGACCAGGGGCAGAAACC and Nell E14(R): TTGCTCAACCTCAATATCC.
The PCR products were purified using QIAquick PCR Purification Kit (Qiagen) and
directly sequenced using the same primer set as above.

BODY AND HEAD MEASUREMENTS
E18.5 fetuses were recovered by caesarean section from nine pregnant females. A
total of 16 wild-type and 19 homozygous mutant fetuses were measured for body length,
head height, head length, and head width. These morphometric measurements were
obtained using a Fisher Scientific Digital Caliper. Two-tailed Student T-test with a Pvalue cutoff of 0.005 was used to analyze the data and determine statistically significant
differences between mutant and wild-type fetuses.

SKELETAL ANALYSIS
Skeletal defects in Nell16R homozygotes were evaluated using standard protocols
for Alizarin Red-Alcian blue staining of intact fetuses (Hogan 1994). Briefly, 13 wildtype and 13 homozygous mutant fetuses were recovered by caesarean section at E18.5
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Table. 3.2: Primers Used to Amplify Mouse Nell1 Genomic DNA.

Primer
Pairs

Sequence of Right Primer

Sequence of Right Primer

Fragmen
t Size

Nell E1AF/
E1AR

GCCCGTCAGAGATA

CTGCCGCCCCGTAG

575 bp

Nell E2AF/
E2AR

TAACTGCCTGGCTGAATCC

GCCTCTGCTCACTCTCAGAAC

519 bp

Nell E3AF/
E3AR

GGCAATCTGGGCTCTTAAATG

GAACAGAAGGCAAAGGCAAG

415 bp

Nell E4AF/
E4AR

GAGTCACGGAAGGTCAAAGC

TCCATGTCAGAAGCTCAAGG

403 bp

Nell E4BF/
E4BR

GCCAAACATACCTATTGCAGTC

TAGTGGGTTTTCCCTCATCG

436 bp

Nell E5AF/
E5AR

GGCTGCTATGAACATAGTGGAG

ATGTGGGAGAGGCTGAAGAG

410 bp

Nell E6AF/
E6AR

TTGTCTGACACTAGGAACAAGT
CAC

GAATGCAGATATCCCCTACTGC

385 bp

Nell E6BF/
E6BR

TTTTGTCTGACACTAGGAACAA
GTC

TTATTTCCCCCTCCAAAAGC

504 bp

Nell E7AF/
E7AR

ACGGGCAGTCTCATTTCAAG

TGAGGGAAACAGTGTTAGGAAC

392 bp

Nell E8AF/
E8AR

GGCTTACTTTGCATGTG

CACACGCTGTCATGGATACC

449 bp

Nell E8BF/
E8BR

ATGTGCAGTTCCTGCAGTTG

CACACGCTGTCATGGATACC

438 bp

Nell E9AF/
E9AF

CAGGTGGATGAAGCCAGTG

TTAGTTGGGTCCCGAACAG

399 bp

Nell E9BF/
E9BF

CAGGTGGATGAAGCCAGTG

GATCACTGTGACCCTTGGTG

449 bp

NellE11AF
/ E11AR

CTTTGCATGCTCCTCTTTCC

CTCCAGCCGATTAACTCTGC

349 bp

NellE12AF
/ E12AR

CCTGATTTCTCTCCCTGGAC

GATGGAGTGAGCAAGACAAGC

399 bp

NellE13AF
/ E13AR

GCACATCAGGAAACATGCTC

GACAGTGGGGAGACGGTATG

492 bp

NellE14AF
/ E14AR

AGCAGGCAAAGAATGCTAGGG

AGTGCACCAACTGGCTTTG

404 bp

NellE15AF
/ E15AR

ATAGACCAGGGGCAGAAACC

TTGCCTCAACCTCAATATCC

421 bp
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Table. 3.2: Continued.

Primer
Pairs

Sequence of Right Primer

Sequence of Right Primer

Fragmen
t Size

NellE16AF
/ E16AR

ATTCTGTGTCCAGAAAGAAAAG
G

TCCCTGGGATGGATACACAC

434 bp

NellE17AF
/ E17AR

ATTTGAAGGGCAGAGTCACG

ATGAGGATGTGGGGCTAATG

278 bp

NellE17BF
/ E17BR

TTCCTCGGTTTCAAGGTTTG

GCCCACATCTTTGGTCTCC

409 bp

NellE18AF
/ E18AR

GCACTGGGCACTTACACTCC

CCAGTCAGCTTACCTTACAGGAA
C

406 bp

NellE18BF
/ E18BR

ACTGGGCACTTAACCTCC

TCAGCTTACCTTACAGGAACAGA
C

402 bp

NellE19AF
/ E19AR

GGTCCAGTTGTCTCCAC

ACAAGGCAGCACAGTTAGGG

464 bp

NellE19BF
/ E19AR

TGTCTCCACTTCGATAGAGCTT
C

ACACTGGCAACCGAGTCAG

470 bp

NellE20AF
/ E20AR

TGGATCATACACATTAGGGTTC
C

TGTCCTCCTGTGAGAACATACAC

464 bp

NellE21AF
/ E21AR

GGAGCTGACCCCTGTGTTC

GTGTGCAGCGGATGAGATAG

507 bp

NellE21BF
/ E21BR

CTGGAATTAAAGGCGTGTGC

CACATCTCCATCAACACGTC

687 bp

Nell CONB
F /CONBR

AGCTCGGTACCGCTGGTG

AGCTTGGTACAAGGCCAATC

450 bp

Nell CONC
F/ CONCR

CACCCTCAACTCTCCCTCAG

TCCACTGGGCCTATTCTCTG

419 bp

NellCOND
F /CONDR

ACCATGTCCCACCCTCAAC

CTGGACCAACAGGTCTACCG

408 bp
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days of gestation from seven pregnant females. The fetuses were soaked in tap water for
2-5 hours, and then briefly in 70°C water and the skin and the internal organs were
removed. The fetuses were fixed in 95% ethanol, stained in Alcian blue (in 95% ethanol
and glacial acetic acid (Sigma-Aldrich, St Louis, MO) for 1-2 days and rinsed in 95%
ethanol. They were then cleaned in 1% KOH for 2-6 hours, counterstained subsequently
in Alizarin Red solution (Sigma-Aldrich) for 2-3 hours and cleared further by placing in
2% KOH overnight. To complete the clearing of the fetuses in order to visualize the
internally stained skeleton, fetuses were incubated further for at least a day in each of the
following series of solutions: 2% KOH/glycerol: Solution I (80:20), Solution II (60:40),
Solution III (40:60), and Solution IV (20:80). Skeletal preps were then stored indefinitely
in the final solution. Skeletal defects of fetuses were further analyzed by using the small
animal Micro Cat system developed at ORNL in collaboration with Dr. Mike Paulus.

HISTOLOGICAL ANALYSIS
Histological analysis was done on 10% Formalin-fixed, paraffin-embedded
sections of E18.5 fetuses (6 mutants and 6 wild-type specimens) recovered by caesarean
section. Haematoxylin and Eosin (H and E), Masson, Periodic Acid Schiff (PAS) was
done according to standard protocol (Carson 1990). Haematoxylin stains nucleic acids
blue while Eosin stains basic proteins in the cytoplasm red. Masson stains cytoplasm,
keratin and muscle fibers red and collagen and mucins blue while PAS stains glycogen,
mucopolysaccarides, glycolipids, and glycoproteins purple. The van Kossa staining was
used to assess the extent of mineralization of vertebral and calvarial bones. Briefly,
sections were dewaxed, rinsed in alcohol and distilled water and treated with 5% silver
nitrate and exposed to a bright lamp for 1-2 hours. Sections were first rinsed in distilled
water and then in 5% sodium thiosulphate for 2-3 minutes and counterstained with eosin
for 1-2 minutes. Sections were then rinsed in distilled water, dehydrated and mounted.
The van Kossa staining stains calcium salts black. Sectioning of the embryos and paraffin
embedding of the sections was done by a commercial histology service, Ridge
Microtome.
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IMMUNOHISTOCHEMISTRY
Expression of Nell1 and Col-10 was detected by a standard avidin-biotin
complex/immunoperoxidase protocol using VECTASTAIN® Elite ABC kit (Vector
laboratories Inc, Burlingame, Ca) according to manufacturer’s protocol with a few
modifications. Briefly, paraffin-embedded sections were incubated at 60°C for few
minutes, dewaxed in xylenes and rehydrated in graded ethanol baths. Sections were
rinsed in tap water for 5 minutes and enzyme-treated for antigen retrieval with 20 μg/ml
Proteinase K (Roche Diagnostics) at 37°C for 10 min, washed in 1X PBS (phosphate
buffered saline, Sigma-Aldrich) and blocked for 20-30 minutes in Blocking buffer (1.55% rabbit serum (Vectastain kit) in 1X PBS). The sections were incubated with antiNell1 (1:100, a kind gift from Dr. Kang Ting, UCLA, California) or anti-type X collagen
(1:30-1:60, Fitzgerald industries, Concord, MA) primary antibodies for 30 minutes at
room temperature or overnight at 4°C and then incubated with biotinylated anti-rabbit
secondary antibody (Vectastain kit) for 30 –60 minutes at room temperature. The sections
were washed in PBS buffer and positive immunoreactivity was detected using Vectastain
ABC reagents and AEC (3-amino-9-ethylcarbazole) substrate (both from Vector
Laboratories) according to manufacturer’s instructions. The sections were then washed in
PBS buffer, rinsed in water and counterstained with hematoxylin QS (Vector
laboratories) for 5-45 seconds. The sections were again rinsed in tap water and mounted
in aqueous mounting medium (Vectamount, Vector laboratories). The Nell1 antibody was
raised against the specific COOH-terminal region of rat Nell1 protein (Kuroda et al.
1999).

HIGH-THROUGHPUT REAL-TIME qRT-PCR ASSAYS
These assays were done in collaboration with Dr. Mark Shannon at Applied
Biosystems as described in Desai et al (Desai et al. 2006). Total RNA from the heads and
bodies of four Nell6R mutant and four wild-type E18.5 fetuses were extracted individually
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(16 RNA samples). DNase1-treated RNA was ethanol precipitated and resuspended in
nuclease-free water. 2.5µg of total RNA was reverse transcribed to cDNA using the
random-priming High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City,
CA).
MULTIPLEX PRE-AMPLIFICATION OF cDNA TARGETS: To enable maximum
sensitivity and detection of hundreds of gene expression targets from a small amount of
cDNA, a novel multiplex PCR pre-amplification strategy was used prior to conventional
quantitative PCR. 225 (219 experimental and 6 endogenous control genes) TaqMan®
Gene Expression Assays (PCR primer/FAM-probe stock solutions) were pooled together
and used in a single PCR to amplify all targets equally from the same cDNA template.
The FAM-probe is a component of the final configuration of the manufactured TaqMan®
Gene Expression Assays and does not interfere with the preamplification process. To
prepare the multiplex pre-amplification primer pool, equal volumes of the 225 TaqMan®
Gene Expression Assays were mixed together, dried under vacuum, and resuspended
with water to generate a multiplex-pooled primer set with a concentration of 180 nM for
each primer. The pre-amplification reaction was set up as follows: A 250 µl volume of
500 ng of cDNA was combined with 250 µl of the multiplex-pooled primers. Then, 500
µl of 2X Multiplex Pre-amplification Master Mix was added to generate the final 1000 µl
of reaction volume (Applied Biosystems). The reaction mix was divided into 50 µl
aliquots in a 96-well PCR tray and cycled on an ABI 9700 thermalcycler under the
following conditions: 95o C for 10 minutes; then 10 cycles at 95o C for 15 seconds; and
60o C anneal/extension for 4 minutes.
REAL-TIME PCR REACTIONS: Pre-amplification products were recombined into
one tube and diluted 1:5 with water. Individual singleplex TaqMan® Gene Expression
Assays for each of the 225 pre-amplified markers, along with 18S rRNA (which was not
included in the pre-amplification reaction due to its high level of expression) were
prepared as follows: 5.0 µl of 2X TaqMan® Universal PCR Master Mix, 0.5 µl of
TaqMan® Gene Expression Assay 20X primer/FAM-probe solution and 2.0 µl of water,
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and 2.5 µl of preamplified cDNA product. For all samples, each assay was carried out in
quadruplicate wells of 384-well plates and run in the ABI PRISM® 7900HT Sequence
Detection System under two-temperature cycling: 95o C for 10 minutes, then 40 cycles of
95o C for 15 seconds and 60o C for 1 minute. CT (threshold cycle) values, the cycle
number at which the PCR amplification fluorescence signal crosses a fluorescence
threshold, were generated using the FAM dye layer setting at a threshold of 0.2 and a
baseline of 3-13.
DATA ANALYSIS: The relative levels of transcripts for each gene in wild-type and
mutant samples were compared following normalization to endogenous control targets.
GeNORM software (Vandesompele et al. 2002) was used to select the two best targets
with the least variation across samples from a collection of 6 potential endogenous
controls (Hprt, Tfrc, Tbp, Gus, Pgk1 and 18s rRNA). Gus and Hprt were selected for
heads, while Gus and Pgk1 were selected for bodies. The geometric mean of the selected
targets was then used as the reference for determining ΔCT values. For each sample,
ΔΔCT values were determined by the following equation: ΔCT Marker = CT Marker – CT
Reference. Statistically significant differences between ΔCT values of wild-type and
mutant groups were determined by a two-tailed t test without assuming equal variances
and with a p value cutoff of 0.005. ΔΔ CTs were also calculated between wild-type and
mutant groups based upon average ΔCT values for each group, and relative fold
differences between them were determined by 2^-ΔΔCT (Applied 2001).
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CHAPTER 4
RESULTS
CHARACTERIZATION OF MOLECULAR BASIS OF THE Nell16R MUTATION
To accomplish this task, the following experiments were conducted: a)
identification of the Nell1 mutation in 102DSJ, b) expression profiling of the Nell1 gene
during mouse development, c) investigation of the impact of the mutation on the
expression of Nell1 gene. Since the mouse Nell1 sequence was not available during the
start of this project, sequencing of the complete coding region of the gene was necessary
to accomplish this task. Characterizing the molecular basis of the 102DSJ was essential in
understanding the gross morphological aberrations and cellular phenotypes that were
observed in the latter part of this study.
In the past two decades ORNL has pioneered and conducted large-scale ENU
mutagenesis experiments to recover ENU-induced mutations at specific segments of
mouse chromosome 7 (Rinchik et al. 1999; Rinchik et al. 2002). One of these experiment
generated mutations mapping to a small segment of mouse chromosome 7 proximal to p
gene and homologous to human chromosome 11p15. One of the loci mutated in this
experiment was l7R6 and it yielded eight recessive neonatal lethal alleles: 88SJ, 335SJ,
2038SJ, 102DSJ, 45DSJ, 11DSJ, 244DSJ, and 141SJ. Trans complementation analysis
with a number of p deletions mapped l7R66R to the same <1 cM segment of chromosome
7 (Fig. 4.1 and materials and Methods) as other l7R6 alleles, with homology to a region
of human 11p15.
EXPRESSION ANALYSIS OF MOUSE Nell1 GENE: Gene content analysis of the
human chromosomal region suggested at least six candidate genes for l7R6
(http://genome.ucsc.edu), including NELL1, which was particularly provocative because
of its overexpression in the prematurely fused sutures of patients manifesting unilateral
coronal synostosis. The pronounced enlarged head phenotype (see fig.4.5), high mutation
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Figure. 4.1: Complementation Analysis. Showing the mapping of the l7R6 locus into an interval
in mouse chromosome 7 (red box) that is homologous to a segment of human chromosome 11p15 where
the Nell1 gene is located. Mouse chromosome 7 is represented by the line with a filled circle at the left
(indicating the centromere) and relative positions of genes and markers are indicated above the line. The 3
crossed circles (88SJ, 335SJ, and 2038SJ) and the 5 filled circles (102DSJ, 11DSJ, 45DSJ, 142DSJ, and
244DSJ) represent 8 alleles of l7R6 including l7R6R6R. Five mutant mouse lines carrying deletions of
varying lengths and surrounding the pink-eyed dilution gene (p) are shown as 46DFiOD, 47DTD,
2MNURF, 8R20 M and 3R30M. Among these mutations, only the 3R30M deletion can complement the
ENU-induced mutations at l7R6 indicating that this deletion does not extend to the position where the l7R6
gene is located. The interval is therefore defined by the proximal deletion breakpoints of the 8R250M and
3R30M mutant mouse lines.
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rate, along with the high-resolution deletion-map position, suggested that recessive
l7R66R mutation might be a loss-of-function allele in the Nell1 gene. To test this
hypothesis, Nell1 gene expression in wild-type and mutant embryos and in wild-type
adult tissues was assayed by Northern blot analysis. The cDNA probe detected a 3.5 kb
transcript in wild-type embryos from E10-18 days of gestation (Fig. 4.2). During
gestation, expression was first detected as early as E10 and from E 14-18 it steadily
increased in the head region and slightly decreased in the body. In adult tissues, normal
expression was observed primarily in adult brain (Fig.4.2). In contrast to wild-type
embryos, the Nell1 expression was barely detectable in 102DSJ mutant embryos (Fig.
4.3A).
The expression analysis of wild-type and mutant alleles were also confirmed by
RT-PCR analysis (Fig. 4.3B). The two cDNA fragments, one short fragment (~ 557 bp)
covering the 5’ end and one long fragment (1465 bp) covering the middle and 3’ end of
the gene were generated by standard PCR (short fragment) and Long Range PCR (bigger
fragment). The expression analysis revealed that only the 5’ end (~ 557 bp) of Nell6R
(102DSJ) was expressed and rest of the gene segment looked degraded (~ 1465 bp) i.e.
drastically reduced band representing the middle and 3’ end of the gene was detected,
while in wild-type and other mutant animals carrying other alleles of Nell1, both of the
bands representing the whole gene were detected. This finding is consistent with the
mutation scanning data (see Fig. 4.4). The point mutation in Nell1 at 1547th bp introduces
a premature stop codon that truncates the protein and the products of such nonsense
mutations are detected and degraded by the cell via a pathway known as nonsensemediated mRNA decay (NMD) (Nagy et al. 1998; Hillman et al. 2004). The degradation
of the nonsense mutation induced transcripts is known to occur from both the 5’ and 3’
end of the transcript. The degradation from 5’ end occurs through decapping and 5’→ 3’
exonucleolytic decay while the degradation from 3’ end occurs through accelerated
deadenylation and exosome-mediated 3’→ 5’ decay. (Chen et al. 2003; Lejeune et al.
2003; Gatfield et al. 2004). In case of nonsense mutation in Nell6R mice, the degradation
of the Nell1 transcript seems to occur from the 3’ end because, 3’ end of the transcript
looks completely degraded (lane 12) while 5’ end of the Nell1 transcripts looks slightly
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Figure. 4.2: Expression of the Mouse Nell1 Gene. Northern blot showing expression profiles
in heads (H) and bodies (B) of wild-type embryos/fetuses (samples 1-8) and adult mouse tissues (samples
9-16). The lane positions, developmental stages and adult tissues are as follows: 1, E10; 2, E12; 3, E14 H;
4, E14 B; 5, E16 H; 6, E16 B; 7, E18 H; 8, E18 B; 9, brain; 10, liver; 11, spleen; 12, kidney; 13, thymus;
14, heart; 15, lung; 16, muscle. The Nell1 cDNA probe detects a 3.5-kb transcript as early as E10 days.
From E14-E18 days, the Nell1 message is abundant in both fetal heads and bodies, increasing dramatically
in the head as development proceeds. Hybridization of the blot with an actin probe serves as control to
compare levels of samples loaded in each lane.

69

A.

B.

1

2

3

4

5

6

7

8 9 10 11 12

Figure. 4.3: Aberrant Expression of Nell1 in l7R6 Mutants. (A). Northern blot showing
expression of Nell1 profiles in heads of E15 l7R6 embryos/fetuses. There is severe reduction in the
expression of Nell1 gene in the l7R6R6 (102DSJ) allele compared to normal levels of expression detected in
wild-type and other three mutant alleles [88SJ (Nell11R), 335SJ (Nell12R), 2038SJ (Nell13R)] at the l7R6
locus. (B). RT-PCR showing expression of Nell1 in E18.5 wild-type and mutant embryos/fetuses. Lane1,
2.5 Kb ladder, lanes 2-6 represent 5’ end (~ 557 bp) and lanes 8-12 represent middle and 3’ end (~ 1465
bp) of Nell1 gene. The slightly reduced expression of the 5’end of the Nell1 was detected in 102DSJ (lane
6) compared to wild-type and other mutants while the expression of rest of the gene (middle and 3’ end)
was drastically reduced (lane 12). See text for details.
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reduced (lane 6).
SEQUENCING OF MOUSE Nell1 cDNA: Even though Nell1 functions are not clearly
understood, the human and rat Nell1 genes have been well characterized in terms of gene
location and sequence analysis. However, at the start of this study there was no mouse
full-length cDNA available. Therefore mouse Nell1 cDNA was generated and sequenced
from BJR strain. Eleven sets of primers were designed based on mouse EST’s
homologous to human Nell1. The full-length cDNA covering the entire coding region
plus 5’ and 3’ untranslated regions was obtained by generating short 300-350 bp
overlapping PCR fragments. A full-length 2862 bp cDNA was generated (GeneBank
Accession #. AY62226) (Fig. 4.4A) with an open reading frame of 2433 bp, which
encodes an 810 amino acid protein. Determination of opening reading frame and
sequence of translated protein was obtained by using NCBI’s ORF finder. The domain
prediction for Nell1 protein was also done by using NCBI’s Conserved Domain database.
The mouse Nell1 is a multi-domain protein with one thrombospondin (TSP)-like domain,
one Laminin G (LamG)-like domain, one EGF-like domain and two van Willbrand factor
C (vWC)-like domains (Fig. 4.4A). The mouse full-length Nell1 cDNA is highly
homologous to human (87% at nucleotide level and 93% at protein level) and rat (98% at
nucleotide level and 97% at protein level) NELL1.
IDENTIFICATION OF Nell1 MUTATION IN Nell16R MICE: To identify the
mutation in Nell16R (l7R66R or 102DSJ) allele, each exon along with the flanking intron
sequences was amplified from genomic DNA and analyzed for point mutation by
heteroduplex analysis using temperature gradient capillary electrophoresis (Li et al,
2002). Heteroduplexes were detected in exon 14. Sequencing of exon 14 for both wildtype and mutants was done directly from PCR products. The sequence analysis showed
that single base pair substitution of T → A that converts a codon for cysteine in to a
premature stop codon (TGT → TGA i.e. Cys → Stop) (Fig. 4.4B). This point mutation at
Cys truncates the 810 amino acid protein at 502nd amino acid and eliminates EGF like
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Figure. 4.4: Identification of the Nell1

Mutation. (A). Mouse Nell1 cDNA sequence

(GenBank Accession No. AY622226) and position of predicted protein domains. Thrombospondin-like
(yellow); Laminin G-like (underlined); van Willbrand factor type C like (blue); calcium binding EGF-like
(grey). The location of the ENU-induced mutation at bp #1546 in the cysteine codon (amino acid #502) are
both highlighted in red text. The premature termination codon introduced at this site will truncate the
protein and remove the EGF-like domains that are essential for the binding to PKC β1. One van Will brand
factor type C like domain will also be missing from the putative mutant protein product. (B). Sequence
electropherograms showing the T to A base change (red arrows) in the wild-type (left) and the mutant
sequence (right) of the Nell1 gene.
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A.

TGT→TGA; Cys→Stop
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Figure. 4.4: Identification of the Nell1 Mutation. Continued.
domains that bind PKC-β1 protein. One von Willbrand factor type C like domain will
also be missing from the mutant protein product and this may interfere with trimerization
of Nell1 protein. In eukaryotes, nonsense mutations like the one observed in Nell1
102DSJ allele are detected and degraded by the cell via a pathway known as nonsensemediated mRNA decay (NMD) (Nagy et al. 1998; Hillman et al. 2004). Therefore
mutation-scanning data is consistent with the observation of severely decreased Nell1
mRNA levels in the mutants. This observation was further confirmed by RT-PCR (see
fig. 4.3B).

DETERMINATION OF THE GROSS MORPHOLOGICAL AND SKELETAL
DEFECTS IN Nell16R MUTANT MICE
Since several previous studies indicate that Nell1 plays a role in cranial
development and osteoblast differentiation, the impact of Nell16R mutation was evaluated
for skull as well as other skeletal defects by comparing wild-type and mutant mice.
Morphometric analysis was conducted on the head and overall body. Detailed skeletal
analysis was also performed using standard chemical stains specific for bone and
cartilage.
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GROSS PHENOTYPES: All of the eight 17R6 alleles were recessive lethal mutations.
All mutant mice including 17R66R hemi- and homozygotes develop till late gestation but
do not survive the physical trauma of birth. Observations on females during delivery
showed that all the hemi- and homozygous 17R66R mutant neonates were born dead,
while remaining mutant fetuses that were retrieved by caesarian section were alive.
However, the mutant mice rescued by caesarian section quickly died because they were
unable to breathe and foster mothers usually cannibalized them. Moreover, additional
defects in the heart and vasculature may also contribute to the death of these mutants (Liu
and Culiat, unpublished data). Mutant hemi-or homozygote fetuses are easily
distinguished from wild-type littermates by their pronounced curled position, enlarged
head region (Fig. 4.5), inability to open their mouth and weak reflexes in extremities. All
the hemi and homoygote mutant l7R6 mice were phenotypically identical and exhibited
enlarged head region and pronounced curled position (data not shown). Heterozygotes
survive to adulthood and breed normally, with no readily visible phenotypic differences
when compared to wild-type mice.
MORPHOMETRIC ANALYSIS: Of all the ENU-induced mutant 17R6 alleles, 17R66R
(102DSJ) is the most severe in terms of abnormal head and body morphology. A total of
16 wild-type and 19 homozygote l7R66r mutant mice were measured for body length,
head height, head length, and head width. Gross anatomical measurements indicated that
compared to their wild-type littermates, homozygous mutant fetuses manifested a
decreased body length due to the pronounced altered curvature of the spine and an
enlarged altered head shape brought about by increased head length (Table. 4.1). No
significant changes in head height and width were detected.
Nell16R MUTANT MICE HAVE SKELETAL DEFECTS IN THE SKULL AND
VERTEBRAL COLUMN: The skeletal phenotype of Nell1 mutants were examined by
Alizarin red - Alcian blue staining of fetuses at E 18.5 days of gestation. Alizarin Red
6R
stains bone while Alcian blue stains cartilage. The skeletal phenotype of l7R6 was

compared with skeletal phenotypes other mutant alleles. All mutants show changes in
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Normal Littermate

102DSJ Homozygote

Figure4.5: Phenotypes of l76R Mutants. Phenotype of l7R66R homozygote mutants at 18.5 days
of gestation. On the right is a fetus homozygous for the l7R66R allele (from stock 102DSJ) showing a very
curled position, enlarged head size and a more spherical head shape, compared to the control littermate
(left). l7R66R mouse fetuses were recovered alive by caesarean rescue because they do not survive delivery
through the birth canal perhaps due to the physical trauma in the neck and spine region brought about by
the abnormal spinal curvature. The phenotypes of the other alleles of l7R6 not shown; they are similar to
l7R66R
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Table. 4.1: Quantitative analysis of changes in body length and head size of Nell16R
homozygous mutants compared to wild-type littermates, measured (in mm) at E18
days of gestation.

Litter
No.

1

2

3

4

5

6

7

8

9

TOTAL

Genotype

No.
Embry
os per
litter

Wild
Type

2

21.49

Mutant

2

Wild
Type
Mutant

Head
Height

± 0.28

10.23

± 0.17

5.95

± 0.01

6.37

19.28

± 0.05

11.5

± 0.70

6.96

± 0.41

6.88

2

17.15

± 0.06

9.72

± 0.20

9.06

± 0.69

6.42

4

16.90

± 0.50

10.37

± 0.75

8.50

± 0.54

6.14

1

21.3

± 0.0

10.1

± 0.0

8.0

± 0.0

6.4

± 0.0

1

18.5

± 0.0

11.0

± 0.0

8.7

± 0.0

6.8

± 0.0

1

19.9

± 0.0

11.0

± 0.0

8.1

± 0.0

6.5

± 0.0

2

17.8

± 0.4

11.2

± 0.4

8.65

± 0.3

6.95

± 0.5

1

23.24

± 0.0

9.77

± 0.0

6.01

± 0.0

6.49

± 0.0

1

20.30

± 0.0

11.15

± 0.0

5.53

± 0.0

6.19

± 0.0

Wild
Type

4

22.69

± 1.64

10.32

± 0.93

5.17

± 0.41

6.42

Mutant

2

18.50

± 0.37

11.44

± 0.32

4.55

± 0.14

6.75

Wild
Type

2

23.86

± 0.37

10.71

± 0.43

5.44

± 0.52

6.66

Mutant

3

19.11

± 0.63

11.2

± 1.45

5.39

± 0.68

6.67

1

22.77

± 0.0

9.47

± 0.0

5.31

± 0.0

6.53

± 0.0

2

18.33

± 0.65

9.94

± 0.88

6.28

± 0.39

6.85

± 0.3

Wild
Type

2

22.32

± 1.4

10.22

±0.88

5.66

± 0.46

6.86

± 0.6

Mutant

2

17.98

± 0.55

10.45

± 1.32

7.19

± 0.41

6.91

±
0.14

Wild
Type

16

21.72

10.21

6.27

6.51

Mutant

19

*18.25

*10.86

*6.98

6.64

Wild
Type
Mutant

Wild
Type
Mutant

±
SEM

±
SEM

± SEM

Wild
Type
Mutant

±
SEM

Head
Width

Head
Length

Wild
Type
Mutant

Body
Length

±
0.35
±
0.54
±
0.78
±
0.33

±
0.37
±
0.21
±
0.61
±
0.06

The body length of mutant fetuses were significantly decreased and the head length increased in
comparison with wild-type mice.
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head shape, spinal curvature and morphology of the ribcage area. Skeletal defects were
6R
1R
very severe in both l7R6 (102DSJ) (Fig. 4.6A) and l7R6 (88SJ) (Fig. 4.6B), while
2R

3R

they were relatively milder in l7R6 (335SJ) (Fig. 4.6C) and l7R6 (2038SJ) (Fig.
6R

1R

4.6D). In the spines of mutants from l7R6 and l7R6 , there is a sharp bend between the
cervical and thoracic vertebrae (arrows). The spinal phenotype is visible as early as E16
(data not shown) and remarkably consistent in severity among mutants of the same line.
The severe phenotype associated with l7R66R fetuses is due to drastically reduced
expression of Nell1 as a result of nonsense mutation and degradation of the Nell1
6R

transcript (see Figure. 4.3). Figure. 4.7 shows skeletal phenotype of l7R6 fetus in detail.
The skeletal analysis clearly showed larger rounder heads, compression of intervertebral
spaces and alteration of spinal curvature, and anomalies in the shape and volume of the
ribcage (Fig. 4.7A and B). The cervical region of the vertebral column displayed the most
dramatic reduction in the intervertebral disc matrix and a pronounced change in spinal
curvature was observed at the juncture of the cervical and thoracic vertebral bones (Fig.
4.7A and B). The enlargement and thinning of the parietal, frontal and interparietal bones
in the skull were readily apparent (Fig. 4.8A-D). The nasal bones were also enlarged but
thinning was not clearly observed in these structures. The consistently decreased staining
by Alizarin Red in the Nell16R calvarial bones indicated decreased ossification in the
mutant. These Nell16R skeletal defects were confirmed by microcomputerized
tomography scanning (Fig. 4.9 and B). The radiographs showed the sharp curvature
change between the cervical thoracic vertebrae (Fig. 4.9A). Moreover, the MicroCat
scanning data suggested lesser and bone density (Fig. 4.9A) and areas of ossification
(Fig. 4.9B) in the Nell16R mutant homozygotes. Although the effect of Nell16R mutation
in the head region was expected, its profound impact on the development of the vertebral
and thoracic skeleton was not anticipated since the deleterious effects of Nell1
overexpression were confined to the growth and differentiation of the calvarial bones
(Zhang et al. 2002).
The gene expression profile resulting from the Nell16R mutation (see Fig. 4.15) is
further supported by standard histological analysis. Histological analysis was done on
both wild-type and mutant E18.5 embryos. The Formalin fixed embryo sections of
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l7R66R (102DSJ)

A.

B.

l7R62R (335SJ)

C.

D.

l7R61R (88SJ)

l7R63R (2038SJ)

Figure. 4.6: Skeletal Analysis of l7R6 Neonates. l7R66R (102DSJ) (A), l7R61R (88SJ) (B),
2R
3R
l7R6 (335SJ) (C) and l7R6 (2038SJ) (D). Mutants manifest changes in head shape, spinal curvature and

morphology of the ribcage area. Both l7R6
categories of defects, while l7R6

2R

and l7R6

6R

3R

1R

and l7R6

show very severe defects in all these three

are relatively milder. In the spines of mutants from l7R6

1R

and l7R6 , there is a sharp bend between the cervical and thoracic vertebrae (arrows).
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6R

A.

B.

Figure. 4.7: Skeletal Phenotype of Nell16R Homozygote Mutant Mouse. At 18.5 days of
gestation. (A). There is alteration of spinal curvature, decrease in intervertebral disc spaces, reduced
thoracic volume, protruding sternum and a slight enlargement of the skull. (B). Close-up of the cervical
region where the most pronounced vertebral compression is located.
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Figure. 4.8: Cranial Defects in Nell16R Homozygote Mutant Mouse. (A) Top view of the
skull showing the increased size of the nasal (Ns), frontal (Fr), and parietal (Pr) bones in Nell6R mutant
mice. (B) Side view of the skull showing enlargement of parietal bones (Pr) in mutant fetal heads. (C).
Enlargement of the interparietal and (D) Frontal bones. (A-D) The calvarial bones of Nell6R mutant mice are
thinner than those of the wild-type and consistently have less Alizarin Red staining, suggesting a lesser
degree of ossification.
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A.

B.

Pr

Pr

D.

C.
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A.

B.

Figure. 4.9: Skeletal Defects in Nell16R Homozygote Mutant Mouse. (A) Radiographs of a
wild-type fetus compared to Nell6R mutant littermate. A pronounced alteration in the spinal curvature occurs
at the cervical vertebrae in the mutant fetuses (arrow). The lesser intensity of signals in the craniofacial and
vertebral skeleton of the mutant suggests lesser bone density.

(B) Images of 3D re-construction of

MicroCat scans for wild-type and mutant fetuses show lesser areas of ossification in the mutant fetal head
(arrow). The observation in earlier skeletal analysis that the mutant calvarial bones are thinner is consistent
with MicroCat scan data showing larger areas of dense bone in the wild-type fetus. These MicroCat sans
again confirm the alteration of spinal curvature and compression of cervical vertebrae observed in Nell16R
mutants.
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vertebral columns were stained with Haematoxylin and Eosin (H and E), Masson and
Periodic acid Schiff (PAS) stains. In the mutant (Fig. 4.10B) vertebral columns,
intervertebral spaces were markedly decreased compared to their wild-type controls (Fig.
4.10A). This observed reduction in intervertebral spaces in mutants may be due to the
decreased ECM production due to mutation in Nell1, which downregulates expression of
specific collagens and non-collagenous proteins due decreased chondrocyte
differentiation (see Real-time qRT-PCR results, page 92 and Fig.4.15). H and E staining
of vertebral bodies shows that in wild-type, cells look well defined and more
differentiated (Fig. 4.10C) while in mutants, cells look less organized and developed
(Fig.4.10D). Compared to their wild-type littermates (Fig. 4.10C), Nell16R homozygous
mice displayed considerable reduction in the amount of extracellular material
surrounding the cells in the developing vertebral body and intervertebral discs (Fig.
4.10D).

EXAMINATION OF THE ROLE OF NELL1 IN OSTEOBLAST AND
CHONDROCYTE DIFFERENTIATION IN THE VERTEBRAL COLUMN
To test the hypothesis that the reduced expression of Nell1 in Nell16R mutant
impairs chondrogenesis and endochondral ossification by decreasing differentiation in
both osteoblast and chondrocytes in the vertebral column, expression of specific
differentiation markers for both osteoblast and chondrocytes was investigated.

LOCALIZATION OF NELL1 EXPRESSION IN WILD-TYPE AND MUTANT
Nell16R FETAL VERTEBRAL COLUMNS: The cell-specific expression of Nell1 in
both wild-type and mutant E18.5 fetal vertebral columns was determined by
immunohistochemistry using anti-rabbit Nell1 antibody. This Nell1 antibody has been
successfully used for immunohistochemistry studies (Zhang et al. 2002). Vertebral
column develops by endochondral ossification. Formation of vertebrae is initiated at the
center of the vertebral bodies and the growth occurs in a radial fashion with chondrocyte
proliferation and differentiation occurring at the central area of vertebrae and the mature
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Wild-type

Mutant

Wild-type

Mutant

Figure. 4.10: Histological Analysis of Fetal Vertebral Column. (A) The normal
architecture of the cervical vertebral column in wild-type E18.5 fetus (sagittal section, Masson staining)
compared with the mutant Nell16R homozygote, (B), showing the reduction of intervertebral spaces between
the vertebral bodies (arrows). See text for details. (C) and (D). Haematoxylin and Eosin staining of sagittal
sections of vertebral bodies (higher magnification) of wild-type (C) and mutant (D) showing lesser amount
of ECM and cellular development of chondrocytes in the mutants.
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bone formation by osteoblasts at the periphery. Decreased expression of Nell1 was
detected in mutant (Nell16R) vertebral columns (Fig. 4.11C and D) compared to wild-type
fetuses (Fig. 4.11A and B). In wild-type vertebral bodies, the expression was restricted to
osteoblasts, which are present at the surface of the vertebral body away from center of
ossification and there was no staining detected in chondrocytes, which are present at the
center of the vertebral bodies, near the site of initial ossification (Fig. 4.11A and B).
There was no staining detected in the intervertebral discs (Fig. 4.11A and B) again
suggesting, expression of Nell1 is restricted to osteoblasts at this stage in fetal
development. In mutants Nell1 expression was restricted to osteoblasts at the surface of
the vertebral bodies and no staining was observed in intervertebral discs. The dark lines
observed in the mutant intervertebral spaces do not represent the staining for Nell1
protein. They are the artifacts introduced during the sectioning and paraffin embedding of
the vertebral column sections. It is possible that chondrocytes in the vertebrae and
intervertebral discs do express Nell1 but at lower levels and is beyond the detection limit
of this assay. Alternatively, chondrocytes may express Nell1 at earlier stages of
ossification i.e. earlier in the development when there is more active cartilage and bone
formation in the embryo. Even though here (Fig. 4.11) the expression of Nell1 in the
spinal cord is not conclusive, the EST data shows that it is expressed in the mouse spinal
cord. The initial phase of chondrocyte proliferation and differentiation in vertebral bodies
and chondrocyte proliferation in intervertebral discs may be regulated by Nell1 secreted
by cells in the spinal cord and in later stages by Nell1 secreted by osteoblasts in the
vertebral bodies.
The Nell1 expression was also detected in wild-type fetal skin. The staining for
Nell1 protein was intense in the epidermal layer of wild-type skin but there was no
staining detected in the dermal or hypodermal layer (subcutaneous layer)(Fig. 4.12A and
B). The staining looks uniform throughout all the five layers of epidermis. In addition to
the epidermis Nell1 expression was also detected in the wild-type skeletal muscle beneath
the skin. In contrast to wild-type fetal skin, Nell1 expression was markedly decreased in
mutant (Nell16R) skin (Fig. 4.12C and D). The staining for Nell1 was barely detectable in
the epidermal layer of mutant skin while no staining was detected in other layers of the
86

A.

Wild-type (10X)

B.

C.

Mutant (10X)

D.

Wild-type (20X)

Mutant (20X)

Figure. 4.11: Expression of Nell1 in Fetal Vertebral Column. Immunohistochemical
staining of sagittal sections through the vertebral columns of wild-type (A) and (B) and mutant (Nell16R)
(C) and (D) E18.5 fetuses showing expression of Nell1. Positive immunoreactivity (coppery brown
staining) for Nell1 was detected in wild-type fetal vertebral bodies, (A) and (B) (higher magnification) but
not in intervertebral discs and its expression was restricted to osteoblasts at the surface of the vertebral
bodies. There is less or no staining detected in the chondrocytes at the center of the vertebral bodies and
chondrocytes in the intervertebral discs. Expression of Nell1 was less in mutant vertebral columns (C) and
(D) [higher magnification]).
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A.

Wild-type (10X)

B.

Wild-type (20X)

C.

D.

Mutant (10X)

Mutant (20X)

Figure. 4.12: Expression of Nell1 in Fetal Skin. Immunohistochemical staining of sections
through the skins of wild-type (A) and (B) and mutant (Nell16R) (C) and (D) E18.5 fetuses showing
expression of Nell1. Intense positive immunoreactivity (coppery brown staining) was detected in the
epidermal layer of the wild type fetal skin and in the skeletal muscle beneath the skin, (A) and (B) (higher
magnification) while Nell1 expression was markedly decreased in mutant skin, (C) and (D) (higher
magnification).
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skin including the muscle beneath the skin. This was an unexpected finding but rather an
important one because mutation in Nell1 affects specific collagens and ECM proteins
(revived in chapter 2) that are also affected in Ehlers-Danlos syndrome, which is also
associated with cartilage and skin defects. These results suggest that the hyper-elastic
skin observed in the patients with certain type (s) EDS with unknown etiology/genetic
defect may be partially due to the mutation in Nel1l gene.
EFFECT OF Nell16R MUTATION ON DIFFERENTIATION OF OSTEOBLASTS
AND CHONDROCYTES IN THE DEVELOPING VERTEBRAL COLUMN:
The skeletal, histological and expression analysis of mutant Nell1 alleles revealed
alterations of head shape and deformities in the vertebral column and suggested
dysregulation of cell proliferation, differentiation and apoptosis. The previous in vitro
studies have demonstrated (Zhang et al. 2002) that downregulation of Nell1 results in
reduced osteoblast differentiation. Both osteoblasts and chondrocytes produce specific
collagens and ECM proteins during the differentiation process. The Real-Time qRT-PCR
analysis (see Fig. 4.15) showed that ECM proteins like tenascins, matrilins, Osf-2, Col X
and Chad are downregulated in Nell16R mutant mice. Therefore, the status of chondrocyte
and osteoblast differentiation in Nell16R homozygotes was investigated for expression of
known markers of osteoblast and chondrocyte (Col X) differentiation and assessed for the
extent of bone mineralization, a measure of differentiation status of osteoblasts. The
expression of Col X in both wild-type and mutant (Nell16R) fetal vertebral column was
examined by immunohistochemistry using anti-Col X antibody (Fig. 4.13). Reduced Col
X staining was detected in mutant vertebral bodies (Fig. 4.13 A and B) compared to wildtype (Fig. 4.13C and D), suggesting decreased differentiation of chondrocyte. The Col X
staining was restricted to chondrocytes in both wild-type and mutant vertebral bodies.
The light blue areas around the rim of the vertebral bodies represent the developing bone,
which contain osteoblast, do not show any staining for Col X. The Col X staining was
observed more in vertebral bodies than in intervertebral discs. The staining observed in
the intervertebral discs may not be due to Col X immunoreactivity, but may be due to Col
II because this particular anti-rabbit Col X antibody is known to exhibit slight cross89

Wild-type (10X)

Mutant (10X)

A.

C

B

D

Wild-type (20X)

Wild-type (20X)

Figure. 4.13: Expression of Col X in Fetal Vertebral Column. Immunohistochemical
staining of sagittal sections through the vertebral columns of wild-type (A) and (B) and mutant (Nell16R)
(C) and (D) E18.5 fetuses showing expression of Col X. Intense positive immunoreactivity (Dark coppery
brown staining) was detected in wild type fetal vertebral bodies as well as intervertebral discs, (A) and (B)
(higher magnification). Staining for Col X was less in both mutant (Nell16R) vertebral bodies and
intervertebral discs, suggesting decreased differentiation of chondrocytes.
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reactivity to Col II.
The degree of bone mineralization (extent of osteoblast differentiation) was
measured by von Kossa staining of both wild-type and mutant (Nell16R) E18.5 fetal
parietal bones and vertebral columns. The results from von Kossa staining of sagittal
sections through the vertebral column and parietal bones (Fig. 4.14A-D) showed
decreased bone mineralization in Nell16R. The cranial (Fig. 4.14 B and D) and vertebral
bones of mutant homozygotes have a lesser number of mineralized areas and exhibit a
highly irregular pattern when compared to wild-type bones (Fig. 4.14 A and C) The
frontal bones display the same defects in bone mineralization as the parietal bones (data
not shown).

DETERMINATION OF THE BIOLOGICAL PATHWAY (S) PERTURBED BY
THE Nell16R MUTATION
A large number of genes and pathways have already been defined in osteogenesis
and chondrogenesis in the skull and vertebral column. The information acquired from
these experiments will aid in placing Nell1 in a particular biological pathway(s) and
relating this to the phenotyping and immunohistochemistry data.
HIGH-THROUGHPUT qRT-PCR: In order to define the genes and pathways that
were perturbed by the Nell16R mutation, qRT-PCR analysis of 219 experimental and 6
control genes was carried out in RNA samples extracted from individual heads and
bodies of four Nell16R mutants and four wild-type E18.5 fetuses. The 219 genes were
carefully selected based on the observed mutant phenotype and the putative domains and
functions of the Nell1 gene. Genes associated with CS (e.g. Runx2, Msx2, Fgfr3), bone
and cartilage development, cell growth and differentiation, neural development and signal
transduction pathways were also included.
This expression analysis showed an association between the loss of Nell1
function and reduced expression of genes for extracellular matrix proteins critical for
chondrogenesis and osteogenesis. The Real-Time qRT-PCR analysis revealed reduced
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Wild-type

Wild-type
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C

B

D

Mutant

Mutant

Figure. 4.14: van Kossa Staining of Vertebral Column and Parietal Bone. van Kossa
staining of sagittal sections through the vertebral columns of wild-type (A) and mutant (B) E18.5 fetuses
showing decreased bone mineralization in the vertebral bodies of (Nell16R) homozygotes. The intensity and
distribution of stained areas (black) are lesser and exhibit an irregular pattern in the mutant fetuses. van
Kossa analysis of sagittal sections through the parietal bones of wild-type (C) and mutant (D) fetuses also
revealed decreased mineralization. In mutant parietal bone (D), the intensity of van Kossa staining is less
and in contrast to the wild-type Nell16R calvarial bones have thinner and more ‘patchy’ pattern of
mineralization. There are larger and more frequent gaps between mineralized regions, similar to the pattern
seen in vertebral bodies (B).
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expression of 13 genes in the head and 28 genes in the body due to Nell16R mutation (Fig.
4.15). Expression of the following 9 genes were affected in both heads and bodies:
Col5a3, Col5a1 Col15a1, Tnxb, Matn2, Osf-2, Chad, and Tnfrsf11b. These affected
proteins are involved in cell adhesion, communication and provide strength and
flexibility to tissues. The most severely affected genes in the head were Tnxb and Col5a3;
in body were Tnxb, Prg4, Thbs3 and Col5a3. The other genes in the body that are
affected by Nell16R mutation such as Tnc, Tnx, Matn3, Chad, Tnrsf11b and Bmpr1a are
known to play a critical role in the development of vertebral column on both human and
mouse (Mansson et al. 2001; Cundy et al. 2002; Gruber et al. 2002; Jackson et al. 2004;
Yoon et al. 2005). The eight out of 21 collagen genes assayed showed significant changes
in expression indicating that the loss of Nell1 influences only a specific set of collagen
subunits. Several affected genes are involved in Ehlers-Danlos Syndrome and other
disorders associated with vertebral column defects. It is rather important to note that
severely affected genes like Tnxb and Col5a3 cause EDS, a severe cartilage defect
(Beighton et al. 1998; Mao et al. 2001). The EDS patients have genetic defects that result
in defective fibrillar collagen synthesis and deposition. Additionally, it has been
suggested that mutation in Col5a3, another gene, which was affected by the Nell1
mutation may account for at least some types EDS in which COL-5A1 and -A2 have
been excluded (Imamura, 2000). Furthermore, one of the six major EDS syndromes, an
autosomal recessive EDS-type VI is characterized by abnormal curvature of the spine,
hypotonia, joint laxity and ocular fragility (Beighton et al. 1998; Mao et al. 2001).
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Figure. 4.15: Gene Expression Profile of Nell16R Mutants Compared with Wild-type
Fetuses (E18.5). Genes with significantly reduced expression in mutant mice are listed from highest to
lowest fold change. Nine genes (in red text) are affected in both heads and bodies. Majority of the genes
that affected by Nell16R mutations encode proteins for the ECM, cell adhesion (Adhn) and cell
communication (Comm) during bone and cartilage development.
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CHAPTER: 5
CONCLUSION AND FUTURE DIRECTIONS FOR ELUCIDATING
THE ROLE OF NELL1 IN CRANIOFACIAL AND VERTEBRAL
COLUMN DEVELOPMENT
SUMMARY OF RESULTS AND CONCLUSIONS
A unique neonatal lethal allelic series of mutations for l7R6 locus in mouse
chromosome 7 was recovered from large-scale ENU mutagenesis experiments conducted
at Oak Ridge National Laboratory. Transcomplementation analysis with a number of p
deletions initially mapped l7R6 to a < 1 cM segment homologous to a region of human
chromosome 11p15 (Rinchik et al. 2002). Based on high-resolution mapping, estimation
of mutation rate, phenotyping and molecular analysis done in this study, and also based
on previously published reports, Nell1 was tested as a candidate gene for l7R6 locus.
High-throughput mutation scanning and sequencing identified a single base change
mutation in the coding region of the Nell1 gene in the102DSJ allele (now designated as
Nell16R). This ENU-induced nonsense mutation in the Nell1 gene truncates an 810 aminoacid polypeptide at residue # 510. This is the first Nell1 loss-of-function mutation
reported to date and thus provided for the first time an in vivo system to study the
consequences of loss-of-function of Nell1. The severe reduction of Nell1 transcripts in
Nell16R homozygotes (presumably due to nonsense-mediated decay) results in neonatal
lethality, an enlarged skull with thinning at the calvarial bone edges, reduced
intervertebral disc spaces, alteration in the vertebral column curvature, abnormal shape
and size of the ribcage. The aberrant expression of Nell1 also leads to decreased
expression of specific extracellular matrix proteins that are known to play crucial roles in
osteogenesis/chondrogenesis and vertebral column development. The range of skeletal
anomalies manifested by Nell16R mutants indicate that the Nell1 gene plays a key role in
both intramembranous and endochondral ossification during early mammalian
development. This study demonstrated that Nell1 is involved in both intramembranous
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and endochondral ossification and regulates both osteoblast and chondrocyte
differentiation in calvarial bones and vertebral column.
Nell1 GENE STRUCTURE, WILD-TYPE Vs Nell16R: Even though the human and rat
NELL1 genes have been well characterized in terms of location and sequence analysis,
there was no full-length mouse Nell1 cDNA available. The only available source was the
Celera database but it contained only a partial sequence. Therefore a full-length (2862 bp)
cDNA (coding region plus both 5’ and 3’ untranslated regions) was synthesized and
sequenced. The mouse Nell1 has an open reading frame of 2433 bp, which encodes an
810 amino acid protein, which is highly homologous to human (92%) and rat (97%)
Nell1 protein. The mutation scanning of genomic DNA of Nell16R and sequencing
revealed a point mutation in the gene that converts a cysteine codon to a premature
termination codon, thereby truncating an 810 amino acid protein at 502nd residue. The
mutation at this residue eliminates EGF-like and vWC-like domains. A loss of EGF-like
domain may have a profound effect on Nell1 function. Nell1 is known to interact and
become phosphorylated by specific isoforms of PKC such as PKC-β1, -δ, and -ζ through
EGF-like domains (Kuroda et al. 1999). PKC-β1 is known to be a key component of cell
proliferation and differentiation pathways in many cells including osteoblasts and
chondrocytes (Nishizuka 1988; Marie et al. 2002; Rosado et al. 2002; Marie 2003).
Additionally, differential expression of PKC isoforms was detected during the 8th week of
developmental age in human fetal vertebral column when most of the chondrogenic
events are occurring. Thus, mutation in exon 14 may disrupt Nell1 interaction with PKCβ1 and interfere with its functions and undermine its role in osteogenesis and
chondrogenesis. Furthermore, loss of one of the vWC-like domains due to a mutation
may also interfere with trimerization of Nell1 protein and hence its function.
Nell1 RNA And Protein Expression: Expression of the gene in wild-type
embryo/fetuses and various adult tissues was assayed by Northern blot. The Nell1
expression was detected as early as embryonic day 10 and from E14-E18 Nell1
expression steadily increased in the head and slightly decreased in the bodies of the
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fetuses. The increasing expression of Nell1 coincides with the time when both
intramembranous and endochondral ossification occur during mouse embryogenesis. In
the skull, the primary ossification centers appear around E13.5 and ossification continues
until birth while the endochondral ossification in vertebral column begins around E14.5
and continues till E18 (Kaufman 1999). In contrast to wild-type, due to point mutation in
the gene, Nell1 expression was barely detectable in Nell16R mutant embryos. The severe
reduction in the Nell1 transcript in Nell16R fetuses may be due to nonsense-mediated
decay (NMD) of the transcript. In eukaryotes, nonsense mutations like the one observed
in Nell16R mice are detected and degraded by the cell via a pathway known as NMD
(Nagy et al. 1998; Hillman et al. 2004).
The cell-specific expression of Nell1 protein was analyzed by
immunohistochemistry. The expression of Nell1 was reduced in mutant fetal vertebral
columns compared to wild-type fetuses. In wild-type, Nell1 was expressed in vertebral
bodies but its expression was restricted to the osteoblasts at the surface of the bone. There
was no expression detected in the chondrocytes in the vertebral bodies or in the
chondrocytes of intervertebral discs. However, one cannot rule out the possibility that it
may be expressed by chondrocytes in both vertebral bodies and intervertebral discs but it
may be below the detection limit of the assay or it may be expressed during the earlier
stages of the development when there is more active cartilage and bone formation taking
place in the embryo. The severe reduction in the Nell1 transcript in Nell16R homozygotes
results in neonatal lethality.
PHENOTYPIC CONSEQUENCES OF Nell1 LOSS OF FUNCTION: The gross
morphological analysis revealed decreased body length and enlarged heads in mutants.
The skeletal analysis along with MicroCat scans showed overall reduction in the density
of the bones, particularly thinning at the edges of the calvarial bones, reduced
intervertebral spaces, alteration in the vertebral column curvature and abnormal shape
and size of the rib cage in the mutant fetuses. The range of the skeletal anomalies
manifested by Nell16R mutation indicate that Nell1 gene plays a key role in both
intramembranous and endochondral ossification during early mammalian development.
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In contrast, overexpression of Nell1 in both human and mouse leads to craniosynostosis
(Ting et al. 1999; Zhang et al. 2002). Certain types of CS are associated with limb and
spinal defects (Anderson et al. 1996; Anderson et al. 1997). The transgenic mouse
overexpressing Nell1 exhibits CS but no vertebral defects (Zhang et al. 2002). However,
reduced expression of Nell1 in Nell16R mouse is associated with both skull and vertebral
column defects. This was the first study to report the involvement of Nell1 in the
development of the vertebral column. It was a novel and an unexpected finding.
Nell1 IN CELL DIFFERENTIATION PATHWAYS: The Nell1 overexpression
experiments conducted in both in vivo and in vitro have clearly shown that Nell1
promotes differentiation and plays a critical role in osteoblast development (Zhang et al.
2003). The Nell1 expression accelerated osteoblast differentiation and mineralization
along with upregulation of differentiation marker genes like Opn, Ocn, and Bmp-7.
Conversely, downregulation of Nell1 in vitro reduced Ocn and Opn expression and
delayed osteoblast differentiation (Zhang et al. 2002) and suggested that reduced levels of
Nell1 would promote osteoblast proliferation in calvarial bones. Additionally, other
studies have reported that Nell1 is involved in endochondral bone formation. Nell1
accelerates chondrocyte hypertrophy and endochondral bone formation within the
distracted maxillary sutures (Cowan et al. 2006) and it also induced premature
hypertrophy and increased apoptosis of chondrocytes with subsequent acrania-like
deformity (Zhang et al. 2006). The results of this study are consistent with these reports.
The reduced expression of Nell1 in Nell16R leads to decreased differentiation of
chondrocytes in the vertebral column and decreased mineralization (as a result of
decreased osteoblast differentiation) in both cranial and vertebral bones. The
immunohistochemical analysis showed decreased Col10 expression, a marker for
chondrocyte differentiation in vertebral bodies and decreased mineralization in both
calvarial and vertebral bones indicating decreased osteoblast differentiation. The
histological analysis done on fetal vertebral bodies was consistent with these results. The
Masson staining of the vertebral bodies showed that in mutants, cells looked less
differentiated and developed compared to wild-type cells. Additionally, the enlarged and
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immature bone formation in the cranial vault along with decreased ossification in the
vertebral column also demonstrates that the aberrant expression of Nell1 increases
proliferation and decreases differentiation in both osteoblasts and chondrocytes. The
Nell1-deficient mice exhibit immature and thinner bones compared to wild type.
Increased proliferation and decreased differentiation of osteoblasts due to reduced
expression Nell1 accounts for the thinner, less mineralized and enlarged calvarial bones.
Only the differentiated osteoblast and chondrocytes secrete ECM proteins (collagenproteoglycan matrix) that bind calcium salts and become mineralized to produce new
bone. However, due to the aberrant expression of Nell1, differentiation along with the
secretion of ECM and subsequent mineralization process is affected. All the previous in
vitro studies and transgenic models of Nell1 have confirmed the role of Nell1 in
craniofacial development and osteoblast biology. However, the broader role of Nell1 in
skeletal development is revealed by the new and the first loss-of-function mouse model
Nell16R. In particular, the alteration of spinal curvature, reduction in the intervertebral
spaces and decreased bone mineralization in these mutants indicate involvement of Nell1
in endochondral ossification and differentiation of chondrocytes.
Nell1 CONTROLS CELL DIFFERENTIATION VIA ECM PATHWAYS: The gene
expression analysis by Real-Time qRT-PCR showed an association between the loss of
Nell1 function and reduced expression of genes for extracellular matrix proteins that are
critical for chondrogenesis and osteogenesis. The majority of the genes with reduced
expression encode ECM proteins such as specific collagens, thrombospondins, tenascins
and matrilins. These proteins provide cell adhesion and communication, and impart
strength and flexibility to tissues. This finding was further supported by the histological
analysis of the fetal vertebral columns. H and E staining of mutant vertebral bodies
showed lesser amount of ECM compared to wild-type. The decreased bone
mineralization resulting from the loss of function of Nell1 gene is also consistent with
reduced levels of ECM detected in these mutant mice. The finding that Nell1 directly or
indirectly affects the expression of at least eight genes (Tnxb, Tnc, Col12a1, Col6a1,
Matn3, Bmpr1a, Thbs3) that are necessary for the development of and/or are specific
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constituents of the intervertebral disc matrix and vertebrae (Miller et al. 1991; Roberts et
al. 1991; Nerlich et al. 1998; Gruber et al. 2002; Jackson et al. 2004; Yoon et al. 2005)
provides additional support for a role for Nell1 in early vertebral column development.
This finding along with the spatio-temporal expression of PKC in vertebral bodies and
intervertebral discs in both human and mice at a time when chondrogenesis and
osteogenesis are initiated provides additional support for the Nell1’s role in the early
vertebral column development. It is interesting to note that EDS-associated genes, Tnxb,
Col5a1 and Col5a3 are severely reduced by the Nell16R mutation and one of the EDS
subtype syndromes, EDS types V1, manifests spinal curvature. Based on these findings, it
can be speculated that Nell1 mutant mice may model certain forms of EDS.
REGULATORS OF Nell1: NELL1 is regulated by several growth factors and
transcription factors. The osteoinductive growth factors like FGF-2, BMPs and TGF-β1
stimulate NELL1 (Zhang et al. 2002). The FGFs control bone formation by regulating the
expression of various genes involved in osteoprogenitor cell proliferation, osteoblast
differentiation and apoptosis via PKC and MAP kinases (ERK and p38 MAP kinases),
which in turn regulate transcription factor like OSF-2/RUNX2 and regulate the expression
of target genes like COL-1, IL-6, OCN, OPN, VEGF, alkaline phosphatase and NELL1
(Marie 2003; Aghaloo et al. 2006). The BMPs are known to regulate the genes involved
in the differentiation of osteoprogenitor cells, endochondral ossification, chondrogenesis
and apoptosis (Hay et al. 2001; Marie et al. 2002) and they are known to mediate their
action through PKC and OSF-2/RUNX2 development pathways (Hay et al. 2001; Lee et
al. 2002). TGF-β, a potent regulator of osteochondroprogenitor cell migration and
proliferation and differentiation of osteoblasts and chondrocytes (Mehrara et al. 2002;
Rosado et al. 2002), is known to up regulate PKC and OSF-2/RUNX2 in both osteoblasts
and chondrocytes and mediate some of its biological function through activating MAP
kinases via PKC and thereby regulate OSF-2/RUNX2 and transcription of target genes
(Mehrara et al. 2002; Rosado et al. 2002).
Furthermore, the NELL1 expression is also modulated by transcription factors
such as MSX-2 and OSF-2/RUNX2. The NELL1 promoter contains multiple conserved
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MSX-2 and OSF-2/RUNX2 binding sites (Lu et al. 2007; Truong et al. 2007). NELL1 is
known to bind with and become phosphorylated by specific isoforms of PKC (Kuroda et
al. 1999). NELLl is also known to regulate the expression of several genes, which are
involved in bone development. It is known to up regulate osteoblastic differentiation
marker genes like OPN, OCN, BSP and chondrocyte differentiation marker COL-10
(Zhang et al. 2002; Cowan et al. 2006).
This study indicates that Nell1 may regulate transcription of several collagenous
and non-collagenous ECM proteins. Matrillins are adopter proteins and form collagenous
and non-collagenous filamentous networks(Mates et al. 2004). They are known to be
involved in cell adhesion, and spreading (Makihira et al. 1999) They interact with COL2, -6, and proteoglycans and several studies suggest that they are involved in both
intramembranous and endochondral ossification (Winterbottom et al. 1992; Klatt et al.
2000; Wiberg et al. 2003). Tenascins are known to regulate cell migration, differentiation
and cell and ECM interactions. TNX binds COL-6 and regulate collagen synthesis
(Minamitani et al. 2004). OPN and OCN are associated with maturation and organization
of the bone and cartilage ECM and prepare the matrix for mineralization(Stein et al.
1993).
Based on findings that the FGFs, BMPs, and TGF-β upregulate PKC and signal
through PKC via OSF-2/RUNX2 and regulate the genes involved in osteogenesis and
chondrogenesis and the association of NELL1 with certain PKC isoforms and its
regulation by OSF-2/RUNX2, it is very clear that these growth factors along with the
transcription factor OSF-2/RUNX2 and NELL, and its down stream targets like specific
collagenous (Col12a1, Col6a1, Col5a1 and Col5a3, Col X) and non-collagenous
(matrillins, tenascins, PRG 4, BMPR-1A, OPN, OCN and BSP) proteins play a major
role in both intramembranous and endochondral ossification.
MODEL FOR Nell1-MEDIATED PATHWAYS. The Figure.5.1 shows the
hypothetical model of Nell1 signaling and function in both craniofacial and vertebral
column development and this was based on the previously published reports and data
gathered from this study. Mutation in Nell1 might disrupt signaling by growth factors via
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Figure. 5.1: The Hypothetical Model of Nell1 Signaling Pathway. In vertebral column
(A) and craniofacial (B) development. See text for details. ↓ - Decreased expression, ↑ - Increased, ↓ Decreased.
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PKC during osteogenesis and chondrogenesis (Fig.5.1). During the vertebral column
development, reduced expression of Nell1 may directly or indirectly decrease the
expression of ECM proteins like tenascins and matrillins and this in turn may affect the
synthesis and deposition of certain collagens (Col5a1, Col5a3, Col6, Col12a1, Col15a1,
and Col17a1). The decreased expression of matrillins may disrupt their interaction with
collagens and proteoglycans and this in turn may lead to decreased osteoblast /
chondrocyte adhesion, spreading, and irregular ossification. Downregulation of tenascins
and Col X may interfere with collagen synthesis, deposition and chondrocyte
differentiation. The decreased expression of matrillins, tenascins and collagens may also
lead to decreased ECM production and vertebral defects. Additionally, aberrant
expression of Nell1 may downregulate the differentiation of specific genes like Chad,
Prg4, Thsb3, Opn, and Ocn and this in turn leads to decreased chondrogenesis and
osteogenesis in the thoracic region and subsequent vertebral column defects (Fig. 5.1A).
During the craniofacial development, mutation in Nell1 might lead to reduced
expression of matrillins and tenascins and this in turn may lead to reduced synthesis and
deposition of specific collagens (Col5a1, Col5a3, Col10a1, and Col18a1) which may
subsequently lead to decreased ECM production, thinning of the bones and immature
bone formation. Furthermore, reduced expression of Nell1 may downregulate the
differentiation of specific genes like Opn and Ocn with subsequent reduction in
osteoblast differentiation and this may in turn also increase the proliferation and decrease
apoptosis in osteoblasts. This in turn may lead to reduced ECM deposition by osteoblasts.
Thus, the disrupted balance between proliferation, differentiation, and apoptosis along
with reduction in ECM may increase skull growth and thinning of the skull bones (Fig.
5.1B).

FUTURE DIRECTIONS AND RECOMMENDATIONS
Despite the fact that understanding of Nell1 mediated pathways is still in its
infancy, the dramatic effect of the protein in bone formation has already led to promising
studies that are paving the way for treating human bone disorders. NELL1 is currently
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being tested as a therapeutic agent for bone regeneration. Many craniofacial defects can
be corrected with bone grafts or bone regeneration after orthopedic or surgical expansion.
Although autografts have been used for a long time, they are limited by availability and
injury to the donor site (Sawin et al. 1998). Therefore there is a great demand for
osteoinductive therapies that will eliminate the use of autografts. Currently BMP-2 and -7
have been approved for human use and have been used successfully to induce bone
formation in craniofacial areas of sheep (Abu-Serriah et al. 2003), mice (Matsumoto et al.
2001), and humans (van den Bergh et al. 2000). However, the BMP therapy is associated
with adverse effects like ectopic bone formation, local inflammatory reaction and various
non-bone specific effects (Valentin-Opran et al. 2002).
NELL1’s osteoinductive properties along with its osteo-chondroprogenitor and
osteoblast cell specificity and its preferential expression in skeletal tissues makes it a
potential candidate for bone regeneration in craniofacial and other skeletal defects.
Currently several researchers are using Nell1 as a therapeutic agent to regenerate bone in
animal models. Nell1 was able to induce bone formation in calvarial defects in a mouse
model (Aghaloo et al. 2006) and in distracted intermaxillary suture in a rat model (Cowan
et al. 2006). Additionally, Nell1 was successfully used to induce spinal fusion in rats (Lu
et al. 2007). In all these animal models, Nell1’s osteoinductive effects were compared to
Bmp-2 and -7 and data gathered from these studies show that Nell1 is as potent as BMPs
in inducing bone formation and exerts its effects more specifically in skeletal tissues than
BMPs.
Even though in the past few years great progress has been made in delineating
Nell1 function and its mode of action, the pathway(s) utilized by Nell1 and the other
players involved in osteogenesis and chondrogenesis still largely remain unclear. The
immediate upstream regulators as well as downstream targets of Nell1 still need to be
identified. In this study, impact of the loss-of-function of Nell1 on the selected genes was
examined. However, only 219 genes were assayed and there may be other genes
(involved in osteoblast proliferation/differentiation, survival and signaling) that are
involved in vertebral column development and are affected by aberrant expression of
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Nell1. With whole genome microarray analysis many new genes, which play critical roles
in endochondral ossification can be identified.
During the vertebral skeleton development, Nell1 may mediate its actions through
interacting with and regulating other genes which are critical for osteogenesis and
chondrogenesis including growth factors, cytokines, extracellular matrix proteins,
transcriptions factors, and genes that are involved in proliferation, differentiation and
death /survival in osteoblasts and chondrocytes.
In recent years, DNA microarrays have enabled researchers to examine the
consequences of loss of function of a particular gene on other genes in the entire genome.
Data gathered from these experiments may aid in finding novel interactions of Nell1 with
other genes or its association with certain biological pathway (s). By identifying the
genes, which are differentially regulated by loss of function of Nell1, we may be able to
determine if Nell1 operates upstream or downstream of these genes or which genes in
osteoblast/chondrocyte growth, differentiation and death are affected. By finding the
genes that are associated with, co-regulated with or regulated by Nell1, we may be able to
better understand its role in both intramembranous and endochondral ossification. Taken
as a whole, the data generated by these experiments will lead to a better understanding of
the role of Nell1 in general, consequences of its mutation and its underlying mechanisms
of action in the developing vertebral skeleton. This information may also help make Nell1
a better therapeutic agent in terms of specificity and efficacy in treating skeletal defects.
This study began with the characterization of the five mutant alleles (88SJ, 335SJ,
2038SJ and 11DSJ) of Nell1 along with Nell16R (102DSJ). However, after initial
phenotyping, expression and skeletal analysis, only Nell16R was chosen for further
characterization, because Nell16R mice exhibited severe skeletal defects and dramatically
reduced Nell expression levels compared to other mutant alleles. One of the other alleles,
Nell11R (88SJ) also showed severe skeletal defects and attempts to find a mutation in that
allele as well as other mutant alleles was not met with success. Mutation scanning was
done on all the 20 exons and only on their flanking intron sequences (~ 40 bp upstream
and downstream of each exons, where ENU is likely to induce point mutations). The
mutation 88SJ and other alleles may be deep inside the intron sequences. By fully
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sequencing Nell1 genomic DNA (all the exons along with intron sequences) we may be
able to identify mutation in these other alleles and see the other functional consequences
of Nell1 mutation and this may lead to a better understanding of the Nell1 function in
osteogenesis / chondrogenesis and possibly its role in other organ systems. By
characterizing other alleles, we may be able to elucidate the full range of Nell1 functions
in skeletal as well as in other systems and identify other yet unknown functions of Nell1
or defects in other organs/systems due to its mutation during the mouse development.
Mutation in Nell1 leads to neonatal lethality, making it difficult to study its
functions in the skeletal as wells other systems. To understand the role of Nel1 in
vertebral column development, conditional knockout mice can be created by using lox P
and by tissue specific expression of Cre recobinase. By selectively knocking out Nell1 in
vertebral column, deleterious effects of Nell mutation on survival of mice can be avoided.
Mice will be born alive and are allowed to develop and thus the effect of Nell1 in
vertebral column can be studied.
Nell1 mediated signaling pathway(s) in both intramembranous and endochondral
ossification can be further elucidated by conducting in vitro studies. The osteoblasts
/chondrocytes can be isolated from the calvarial bones and vertebral column and treated
with osteogenic factors like FGFs and BMPs. Upregulation of Nell1 and activation of
MAP kinases (ERK/p38/JNK) pathways can detected by Western blot analysis.
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